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An array of powerful mathematical tools can be used to identify the key un-
derlying components and interactions that determine the mechanics of biological
systems such as the immune system and its interaction with cancer. In this disser-
tation, we develop mathematical models to study the dynamics of immune regulation
in the context of the primary immune response and tumor growth.
Regulatory T cells play a key role in the contraction of the immune response,
a phase that follows the peak response to bring cell levels back to normal. To
understand how the immune response is regulated, it is imperative to study the
dynamics of regulatory cells, and in particular, the conditions under which they are
functionally stable.
There is conflicting biological evidence regarding the ability of regulatory cells
to lose their regulatory capabilities and possibly turn into immune promoting cells.
We develop dynamical models to investigate the effects of an unstable regulatory T
cell population on the immune response. These models display the usual character-
istics of an immune response with the added capabilities of being able to correct for
initial imbalances in T cell populations. We also observe an increased robustness
of the immune response with respect to key parameters. Similar conclusions are
demonstrated with regards to the effects of regulatory T cell switching on immun-
odominance.
TGF-beta is an immunoregulatory protein that contributes to inadequate anti-
tumor immune responses in cancer patients. Recent experimental data suggests that
TGF-beta inhibition alone, provides few clinical benefits, yet it can significantly
amplify the anti-tumor immune response when combined with a tumor vaccine.
We develop a mathematical model to gain insight into the cooperative interaction
between anti-TGF-beta and vaccine treatments. Using numerical simulations and
stability analysis we study the following scenarios: a control case of no treatment,
anti-TGF-beta treatment, vaccine treatment, and combined anti-TGF-beta vaccine
treatments. Consistent with experimental data, we show that monotherapy alone
cannot successfully eradicate a tumor. Tumor eradication requires the combination
of these therapeutic approaches. We also demonstrate that our model captures the
observed experimental results, and hence can be potentially used in designing future
experiments involving this approach to immunotherapy.
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In this dissertation we consider the dynamics of immune regulation in two
contexts:
1. Determining the contribution of regulatory mechanisms to the contraction of
a normal cell-mediated immune response (Chapters 2 and 3).
2. Determining the effectiveness of techniques for overcoming immunoregulatory
mechanisms that are exploited by cancer (Chapter 4).
In this chapter we introduce and briefly discuss highlights from the biological
background that is relevant to the present work. We also discuss general techniques
that are used in addressing such biological questions with mathematical models.
1.1 An Overview of the Cellular Immune System
Adaptive immunity (in contrast to innate immunity) refers to antigen-specific
defense mechanisms employed by the immune system to remove a foreign anti-
gen. There are two major branches of the adaptive immune system; humoral and
cell-mediated immunity. Humoral immunity involves the production of antibody
molecules and is mediated by B-lymphocytes. Cell-mediated immunity involves the
use of cytotoxic T-lymphocytes to induce apoptosis (cell death) in infected cells [79].
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While much modeling and experimental work has been done on humoral immunity
(e.g [3, 30, 99] or Chapter 2.1 of [73]), this dissertation focuses on mathematical
models of the cell-mediated immune system.
The primary cell-mediated immune response is a process by which the human
immune system responds to a foreign antigen. Upon pathogen invasion, antigen pre-
senting cells (APCs) must migrate to the lymph nodes and present the pathogen. A
näıve T cell with the corresponding specificity will then proliferate and differentiate
into cells with a range of functionality. The two main classes of these T cells are
helper T lymphocytes (also known as Th cells or CD4+ T cells) and cytotoxic effec-
tor T lymphocytes (also known as CTLs or CD8+ T cells). The main functionality
of helper T cells is to aid in activating and directing other immune cells, while cyto-
toxic T cells primarily induce apoptosis in infected cells. Upon clearing the antigen,
the expansion phase is followed by a contraction phase in which the immune system
must retract to a resting, stable state. This process in mediated by a number of
regulatory mechanisms (regulatory T cells, myeloid derived suppressor cells, IL-10,
CTLA4, TGF-β, etc.). The artifacts of the preceding antigen exposure are memory
T cells. These are antigen specific T cells that persist after pathogen clearance and
aid in generating a more effective response to subsequent presentations of the same
antigen (See Figure 1.1) [79]. What follows is a description of the key lymphocytes














(a) A diagram showing the process by which the cellular immune system responds to a pathogen.
Upon recognition of an infected cell, antigen presenting cells (APCs) will present the pathogen to
helper T cells. Helper T cells will aid in activating and directing cytotoxic effector T cells to the
infected cells. Cytotoxic T cells then induce apoptosis in infected cells.
I. Activation
I. Activation II. Expansion III. Contraction IV. Memory
(b) A diagram showing how antigen specific T cells with a certain specificity (blue) will expand and
contract into memory cells upon activation by their corresponding antigen. Cells that are blue with
yellow centers stand for cells that are becoming inactive through the immune contraction process.
Cells remaining in phase IV are the memory cells that persist after pathogen clearance.
Figure 1.1: Cellular immune response schematic.
Helper T Cells (CD4+ T Lymphocytes)
Helper T cells are immune cells that do not have the ability to induce apoptosis
in infected cells. Instead, these cells provide essential co-stimulatory signals that are
involved in the activation, proliferation and maturing processes of other components
of the immune system. Upon activation by the presence of a pathogen, helper T cells
proliferate by releasing a cytokine called Interleukin-2 (IL-2) which acts on helper
3
cells in an autocrine fashion. These activated näıve T cells will then differentiate
into Th1, Th2, or Th17 cells depending on the cytokine environment. The selection
of the type of helper T cell dictates the type of immune response that is elicited:
IFN-γ drives Th1 cell production while IL-10 and IL-4 inhibit Th1 cell production.
Conversely, IL-4 drives Th2 cell production and IFN-γ inhibits Th2 cells. Th17
cells produce IL-17 and were initially implicated in autoimmune diseases but are
now thought to have their own (yet not well-characterized) effector and regulatory
functions. Helper T cells are not only the driving force in the initial stages of
immune expansion, but are also crucial to the contraction phase of an immune
response through their relation to regulatory T cells (addressed in further detail
below) [79, 96].
Regulatory T Cells (CD4+CD25+FoxP3+ T Cells)
Until recently, the discussion about the existence of regulatory T cells, has been
highly contentious. Lately, concrete evidence has arisen showing that the normal
immune system produces a population of T cells that are specialized for immune
suppression [94]. These cells are recruited and activated during an adaptive immune
response and are critical in preventing excessive immune reactions. They play a
key role in the contraction phase of the immune response after invading pathogens
have been successfully tackled. Along with the role they play in contracting a
normal immune response, an additional function of regulatory T cells (Tregs) is
to regulate immune responses that may lead to autoimmunity. Regulatory cells
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comprise approximately 5-10% of the mature CD4+ T cell subpopulation in mice
and humans. They differentiate from varying sources and are affected by a number
of immunosuppressive cytokines (TGF-β and IL-10) as well as immunostimulatory
cytokines (IL-2) [94, 79].
There are two types of CD4+CD25+FoxP3+ regulatory T cells. The first
type, Thymus Derived Tregs, originate in the thymus and represent a distinct T
cell lineage, while Antigen Induced Tregs are regulatory T cells that, depending on
environmental signaling, differentiate from näıve T cells and acquire their regulatory
function in the periphery. The molecular mechanism by which regulatory T cells
exert their regulatory activity has not been definitively characterized and is the
subject of intense research [96].
Cytotoxic T Cells (CD8+ T Lymphocytes)
Cytotoxic T cells are a sub-group of T lymphocytes that are capable of induc-
ing death in a number of “target” cells. Targets may include:
• virus-infected cells,
• cells infected with intracellular bacterial or protozoal parasites,
• allografts such as transplanted organs,
• cancer cells.
Cytotoxic T cells express T-cell receptors (TCRs) that can recognize a specific anti-
genic peptide. In general, the role of CD8+ T cells is to monitor all the cells of
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the body, ready to destroy any cells that express the antigen peptides that they
recognize.
1.2 A Brief Overview of Cancer Biology
Cancer is the leading cause of death in the western world and is the subject of
intense research, yet a widely-accepted, formal definition of the disease eludes the
scientific community. In [93], Ruddon defines cancer as “an abnormal growth of cells
caused by multiple changes in gene expression leading to dysregulated balance of cell
proliferation and cell death and ultimately evolving into a population of cells that
can invade tissues and metastasize to distant sites, causing significant morbidity
and, if untreated, death of the host.”
In [48], cancer biologists Hanahan and Weinberg identify six underlying capa-
bilities that are acquired by cancer cells during tumor development. These hallmarks
include the ability of cancer cells to:
1. Sustain proliferative signaling.
2. Evade growth suppressors.
3. Resist cell death.
4. Have limitless replicative potential.
5. Induce angiogenesis.
6. Invade tissue and metastasize.
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Revisiting [48], in 2001, Hanahan and Weinberg extended the hallmarks of
cancer to include [49]:
7. Deregulating cellular energetics.
8. Avoiding immune destruction.
9. Tumor-promoting inflammation.
10. Genome instability and mutation.
Over the past 125 years, there have been a number of important milestones in
cancer research. Examples include the discovery of tumor angiogenesis, the link be-
tween environmental agents and cancer, and more recently, the genetic basis for cer-
tain cancers (for a full discussion of milestones, see [40]). In the past 10 years, there
has been an increased effort towards targeted cancer therapies. These guided thera-
pies hope to treat cancer while avoiding the toxic effects of traditional chemotherapy
treatments. Molecular-targeted treatments such as trastuzumab for breast cancer
and imatinib for chronic myelogenous leukemia have proved effective at targeting
and killing cancer cells while causing less damage to healthy, normal cells. Other
types of targeted treatments currently under investigation include cytokine therapy,
anti-angiogenic therapy, and vaccination [40].
1.2.1 Tumor Immunology
The relationship between cancer and the immune system is quite complex.
Burnet called the ability of the immune system to detect tumor cells and destroy
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them “immune surveillance” [19]. In general, the process of immune surveillance is
as follows. In the initial phases of tumor formation, the immune system is able to
recognize and destroy potential tumor cells. This is followed by an “immunoedit-
ing” phase in which immune elimination is not completely successful and the tumor
acquires the necessary mutations to avoid destructive immune processes. The fi-
nal phase, the tumor escape phase, begins once some tumor cells have acquired
the necessary mutations to avoid all immune processes and the tumor is able to
grow unimpeded. It is in the tumor escape phase that a tumor becomes clinically
detectable [79].
A summary of many of the mechanisms by which immune evasion occurs is
provided in Table 1.1. We present a mathematical model of treatments designed to
overcome some of these mechanisms in Chapter 4.
1.3 Overview of Mathematical Modeling of Biological Processes
Recent advances in scientific methods have led to a plethora of data in many
biological disciplines. But, contrary to conventional thought, more data does not
necessarily imply a better understanding of the topic. In mathematical biology, our
general goal is to synthesize biological information by identifying the key underlying
components and interactions that determine the qualitative mechanics of a biological
system. To approach this goal, we make simplifying assumptions about a biological
system and analyze the simplified system to glean information that may be inferred
about the original biological system. This analysis involves an array of powerful
8
Mechanism Description
Low immunogenicity Some tumors do not express adhesion
or co-stimulatory molecules that can be
presented by APCs.
Tumor treated as self antigen Tumors express self antigens that are not
easily recognized by the immune system.
Antigenic modulation A tumor might initially express recog-
nizable antigens but lose them or change
them as the disease progresses.
Tumor induced immune suppression TGF-β secreted by tumor cells directly
inhibits immune cells and induces acti-
vation of regulatory T cells.
Tumor induced privileged site Tumors can create a physical barrier
shielding themselves from the immune
system.
Table 1.1: Mechanisms by which tumors avoid immunosurveillance.
mathematical and statistical tools.
1.3.1 Biological Scale and Mathematical Technique
Two key decisions that must be made when modeling a biological system
are the physical scale at which the biological components are addressed and the
mathematical modeling techniques to be used. Figure 1.2 summarizes these aspects.
In mathematical models of biological phenomena, one of the smallest scales
that is typically considered is the genetic scale. There are models of gene expression,
gene assembly, and gene regulation [6, 46, 72]. At the intracellular scale, mathemat-
ical models are used to study questions pertaining to signaling networks, the cell
cycle, or cell decision making [39, 51, 80]. Intercellular models seek to characterize




















Figure 1.2: Different mathematical techniques and biological scales that are com-
monly used in mathematical models of biological processes. Work in this dissertation
is based on differential equations as a mathematical technique and intercellular as
the biological scale.
scale, a cell is considered as a single unit and models belonging to this category can
be used to characterize interactions between cells of different functionality. Model-
ing at the tissue or epidemiological level involves large scale models of entire systems
where those systems could be within organism (see [101]) or across organisms (see
[35]). Recently, increases in computational capabilities have led to the development
of multi scale models that seek to combine studies conducted at different scales.
These mulitscale models may describe a system at many different spatial and time
scales and strive to connect these scales to create a more comprehensive system (for
example see [12]).
Many mathematical techniques are used to answer questions at each of these
biological scales. Statistical analysis of data can give information about data and
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clustering, but time dependent information is lost for many such methods. Time
dependent approaches such as ordinary differential equations (ODEs), delay differ-
ential equations (DDEs), and partial differential equations (PDEs) may be used to
discover dynamical information about a process. Techniques for analysis of differen-
tial equations are well developed and provide a basis for theoretical understanding.
ODEs can be used in a system with homogeneous spacing where events occur on
similar time scales. If spatial constraints or differing time scale constraints are a
factor, PDEs are a commonly used device. DDE models are useful in cases where
current conditions are dependent on conditions at a previous time. Agent based
models can capture stochastic properties and emergent behavior, however due to
computational complexity, these techniques are typically restricted to being used to
model a small number of components.
The techniques and scale chosen in this work are highlighted in white in Figure
1.2. The questions we address in this work concern the overall time dynamics of
populations of cells. Since the interactions of interest occur between cells and each
cell of a specified type is assumed to have similar characteristics, we have chosen
to model at the spatial level of intercellular activity. Our interest in the dynamics
of these populations over time with little concern for spatial aspects, leads us to
consider ODE and DDE models.
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1.3.1.1 Modeling Cell Interactions
Mass action
A guiding principle of mathematical modeling that is frequently used in this
work is the principle of mass action. The law of mass action is commonly used in
modeling bio-chemical interactions using ODEs. This law originates from principles
of enzyme-substrate reactions and states that when two or more reactants are in-
volved in a reaction, their reaction rates are proportional to the product of their
concentrations. The law of mass action relies on two assumptions:
1. The medium in which the interaction occurs must be well mixed. Under this
assumption, the concentrations may depend on time but not on space.
2. The size of each species must be on the same order of magnitude. Under
this assumption, the individual random probability of interactions does not
need to be accounted for. Calculations using mean interaction probabilities
are sufficient.
In the context of intracellular modeling, this law states that the interactions between
two populations of cells occur proportionally to the number of collisions between cells
from those two populations. Mathematically, if population [ES] is formed through





where k is the kinetic coefficient of the interaction [15].
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Feedback Mechanisms
A key component in determining the dynamics in intercellular systems is feed-
back between cell populations. The goal in modeling feedback mechanisms is to
account for how the process of activation and inhibition affects dynamics within a
network of cell interactions. There are three types of feedback loops that can exist
between two populations of cells. These are mutual activation, activation/inhibition,







Figure 1.3: Feedback interactions between populations X and Y. (a) Positive feed-
back: Both populations contribute to the production of the other. (b) Negative
feedback: Population X activates the production of Y which inhibits the production
of X. (c) Double negative feedback: X and Y mutually inhibit each other.
In a positive feedback loop, small disturbances are amplified, increasing sensi-
tivity to positive stimulation. Negative feedback loops can contribute to the stabil-
ity and robustness of a system because this type of loop is resistant to fluctuations
within the system. This type of feedback is one way to model a system designed to
remain in homeostasis (equilibrium). Double negative feedback loops can be crucial
in modeling cell switches and cell decision making [42, 50]. Under proper conditions,
the coupling of feedback networks in differential equations determines the dynamics
and stability of the system.
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1.3.2 Model Parameterization
Model parameterization is an important aspect of qualifying the validity of a
mathematical model. The parameters of mathematical models must be biologically
relevant and physically meaningful. Parameters may be obtained from experimental
data, however many model parameters are not available either because they cannot
be measured using current technology, because the experiments are too expensive
to conduct, or because they were never measured. Consequently, mathematical and
statistical methods are commonly used to estimate unknown parameters and to
determine the sensitivity of the model to those parameters. Unknown parameters
can be estimated using techniques such as least squares, latin hypercube sampling
or a Lineweaver-Burke plot [15, 52, 74] to name a few. Sensitivity analysis can be
performed using a number of methods such as one-at-a-time sensitivity, differential
sensitivity analysis, or partial rank correlation coefficients [47]. Sensitivity analysis
helps to identify the key parameters that control the dynamics of the system. This
can assist in validating the model with respect to current experiments/theory. It
can also be used to guide experimentalists in future experimental design.
1.3.3 Computation
All computations in this work were done using Matlab Student Version 7.10.0.
The Matlab function ODE23 was used for solving systems of ordinary differential
equations. This algorithm uses a variable step Runge-Kutta 23 method [98]. For
simulations involving delay differential equations, the Matlab function DDE23 was
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used. This algorithm extends the methods of ODE23 to obtain numerical solutions
of systems of delay differential equations with constant delays [98].
1.4 Overview of Dissertation
In this dissertation, we develop mathematical models to study the dynamics
of immune regulation. We focus on immune regulation in the context of the primary
immune response and tumor growth.
In chapters 2 and 3 we develop mathematical models of the primary immune
response. We focus on two immunoregulatory mechanisms: immune contraction
through adaptive regulation and functional switching of regulatory T cells. In Chap-
ter 2, we study these immunoregulatory mechanisms in a simple ODE model. This
model displays the expected expansion/contraction dynamics. A further exploration
of these immunoregulatory mechanisms is done in the context of a more detailed
model of the immune response in Chapter 3. We show that when compared to pre-
vious mathematical models, our model shows increased robustness with respect to
key parameters. This model is also used to study the effects of regulatory T cell
switching on immunodominance.
In Chapter 4, we highlight how immunotherapy might be used to overcome
the effects of two regulatory agents exploited by cancer: regulatory T cells and
the Transforming Growth Factor (TGF)-β protein. The goal of this study is to
understand part of the complex interplay between cancer, the immune system, and
the immunoregulatory mechanisms that lead to ineffective immune responses. We
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develop an ODE model to gain an insight into the cooperative interaction between
anti-TGF-β and vaccine treatments. This model is based on the experiments of [106].
Our model is shown to be capable of capturing the observed experimental results,
and hence it can be potentially used in designing future experiments involving such
an approach to immunotherapy.
Closing remarks about the work are given in Chapter 5.
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Chapter 2
Functional Switching and Stability of Regulatory T Cells
2.1 Introduction
The magnitude and effectiveness of an immune response depends largely on
the balance of positive and negative signals communicated by various components of
the immune system. In a recent Nature article, Sakaguchi outlines recent biological
evidence regarding the stability of regulatory T cells (Tregs) [94]. In the past, the
T cell lineage has been assumed to progress downstream towards more differenti-
ated cells. Contrary to this dogma, Tregs were recently discovered to be able to
differentiate “sideways”, halting their regulatory function and becoming effector T
cells that secrete pro-inflammatory cytokines. Immunologists are currently working
towards characterizing the conditions under which this conversion may happen. In
order to understand how regulatory T cells regulate immune responses, it is imper-
ative to investigate how they are produced and the conditions under which they are
functionally stable.
While many mathematical models examine T cell lineage and differentiation
[21, 43, 53, 119], here we develop a mathematical model that includes the novel
consideration that regulatory T cells may lose their regulatory capabilities. Previ-
ous work has used a number of mathematical techniques in the areas of nonlinear
dynamical systems and agent based modeling to investigate questions such as the
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Th1 versus Th2 immune responses [43, 119] and immune cross-regulation [21, 53].
In this work, we are investigating how immune regulation arising from regulatory
T cells is affected by a feedback mechanism in which helper T cells may become
regulatory T cells and vice versa.
The remainder of this chapter is organized as follows: In Section 2.2.1, we
review the various hypotheses concerning immune contraction and argue in favor
of active suppression of immune responses by regulatory T cells. Section 2.2.2 de-
scribes the biological system highlighted by Sakaguchi and presents the experimental
evidence used as a basis for our mathematical model. In Section 2.3, we present
an ODE model of helper and regulatory T cell dynamics. Results characterizing
the effects of Treg switching are included in Section 2.4. Closing remarks are given
in Section 2.5. A further exploration of this mechanism in the context of a more
detailed model of immune response will be carried out in Chapter 3.
2.2 Biological Background
2.2.1 Immune Regulation via Adaptive Regulation
The mechanisms by which the immune system contracts after an infection are
debated. Razvi et al. demonstrated that apoptosis is the principal mediator of
T cell contraction. Their experiments showed that the highest rate of apoptosis
occurred at the peak of the T cell response. This led them to conclude that cells
are programmed to proliferate for a fixed amount of time, after which they die
[84]. An alternative point of view focuses on a division-based cell program. In this
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case, cells would be programmed to divide a given number of times before dying.
Renno et al. came to this conclusion when they studied programmed cell death in
mice [87]. Yet another supported theory is that of adaptive regulation. Under this
theory, during the course of an immune response, negative feedback from regulatory
T cells suppress the activation of conventional T cells thereby retracting the immune
response [104].
Various mathematical models have been developed in order to study the impli-
cations of the different hypotheses regarding immune contraction (see [4, 58, 116]).
We review these models and make the mathematical argument for active suppression
in Section 3.1.1. Here, we present the biological argument for immune contraction
through Tregs.
The theory of adaptive regulation is supported by the work of Taams et al.
who concluded that active suppression of conventional T cells by regulatory T cells
is a viable possibility due to evidence that passive competition of resources (access
to APCs) cannot account for the decay of the immune response [104]. It has been
known for many years that regulatory T cells exist in the lymph nodes. But in
2004, Baecher-Allan demonstrated that Tregs are also present in the periphery of
humans [8]. These peripheral Tregs can come from näıve T cells that have acquired
a Foxp3 expression [5, 25, 68] or by trafficking from the lymph nodes to the site of
inflammation using homing receptors similar to those used by other effector T cells
[11, 54, 97]. It has also been shown that natural Tregs can expand clonally following
antigenic stimulation and retain their suppressive function after expansion [41, 65,
117, 118]. Regulatory T cells have also been shown to suppress the proliferation
19
and differentiation of näıve T cells. They can also suppress the activities of mature
helper T cells, mature cytotoxic T cells, natural killer cells, B cells, macrophages,
and dendritic cells [78, 100, 105, 110].
The experimental evidence supports the notion that regulatory T cells exist
at the site of an infection either through the homing of naturally occurring Tregs
or through the induction of näıve T cells in the periphery. Similar to other T cells,
Tregs activate and proliferate upon antigen specific stimulation. After expansion,
they retain the ability to suppress many of the immune cells involved in the im-
mune response. This makes a strong argument for regulatory T cells being a key
mechanism of contraction of the immune response.
2.2.2 Concerning Treg Stability
A number of cytokines are essential to regulatory T cell function. These include
the immunosuppressive cytokines TGF-β, Interleukin-10 (IL-10), and the immunos-
timulatory cytokine Interleukin-2 (IL-2). IL-2, the majority of which is derived
from Th1 effector T cells, is indispensable for the maintenance of Foxp3+ Treg cells
and is functionally essential for Treg development. IL-2 maintains Foxp3+ natu-
ral Tregs, triggers cell expansion at high doses, and facilitates TGF-β dependent
differentiation of näıve T cells to Foxp3+ Tregs. Collectively, these factors ensure
a remarkably constant number of Foxp3+ Treg cells in the immune system (about
10% of all T cells expressing the surface marker CD4), with a general increase only
at sites of inflammation [96, 94].
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In [94], Sakaguchi outlines experimental findings concerning the interactions
between cytokine signaling, helper cell differentiation and the conditions under which
regulatory T cells might convert into pro-inflammatory cells. A diagram of CD4+
T cell differentiation along with the cytokines that mediate that of differentiation
are shown in Figure 2.1. Interleukins 2 and 12 drive Th1 cell production. Th1 cells
are specialized at confronting intracellular pathogens. Interleukins 4 and 10 inhibit
Th1 cell production while promoting the Th2 phenotype which works towards the
elimination of extracellular pathogens. Th17 arise from a combination of Interleukin-




















Figure 2.1: CD4+ T-cell differentiation. The thymus produces näıve T cells, which
can differentiate into effector T cells, including Th1, Th2, Th17 cells, and Tregs
following stimulation with antigens. In the periphery, the balances of TGF-β and
IL-2 determine whether a helper T cell becomes a regulatory T cell and whether a
regulatory T cell becomes a helper T cell.
Treg conversion, the process of regulatory cells halting expression of Foxp3 and
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secreting pro-inflammatory cytokines, may happen only under certain conditions.
The experimental evidence highlighted in [94] is as follows:
1. Regulatory T cells vary in Foxp3 expression and therefore in their susceptibility
to conversion. While it is possible that all regulatory T cells are subject to
conversion, it is also plausible that only a certain fraction of Foxp3+ Tregs
may be plastic [120]. This could be due to variations in Foxp3 expression due
to T cell lineage, maturity, genetic and environmental factors [55, 120].
2. Rubtsov et al. show that Treg cells are highly stable under certain conditions
in terms of both Foxp3 expression and their suppressive function, with few
cells converting into effector T cells [92]. Sakaguchi points out that this is not
necessarily contradictory to previous known data and outlines ways in which
this data can be consistent with other experiments.
3. When Foxp3+ Treg cells are transferred to T-cell-deficient mice, the co-transfer
of T cells that do not express Foxp3 or the infusion of IL-2 prevents conversion
of the Foxp3+ Treg cells to effector T cells. If Treg cells are transferred on their
own to T cell deficient mice, Foxp3- T cells that have formed from Foxp3+
Treg cells will produce IL-2, which inhibits further conversion of Foxp3+ Treg
cells in a negative-feedback loop [37].
2.3 Mathematical Model
We consider a simplified version of the biological system and develop a dy-
namical system to investigate the effects of T cell functionality switching on T cell
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immunity. A schematic of the biological system is shown in Figure 2.2. We con-
sider two cell populations: helper T cells and regulatory T cells. The helper T
cell compartment combines the three types of helper T cells: Th1, Th2, and Th17
while the regulatory T cells compartment encompasses both naturally occurring and
antigen induced regulatory T cells. We consider two cytokines that are primarily
responsible for the facilitation of the transition between these cells. These are the
















Figure 2.2: A simplified version of the biological system represented in Figure 2.1.
This is the basis for our mathematical model. There are two cell populations: helper
T cells and regulatory T cells. The helper T cell compartment combines the three
types of helper T cells: Th1, Th2, and Th17 while the regulatory T cells compart-
ment encompasses both naturally occurring and antigen induced regulatory T cells.
Two main signaling proteins mediate this transition. They are IL-2, represented by
S1 and TGF-β, represented by S2.
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Our mathematical model is written as the following system of ODEs:
dH
dt






− δ0H − δ1RH, (2.1)
dR
dt





S1 = ξH and S2 = βR.
In this model, we follow the dynamics of helper T cells, denoted H(t); and regulatory
T cells, denoted R(t). We model the signals between these cells in a way similar
to [119]. We assume that the signals S1 and S2 are being produced by helper and
regulatory T cells, respectively. T cell recruitment and activation depend on these
cytokines. S1 represents those cytokines predominately produced by helper T cells.
Therefore although S1 should be thought of as primarily representing IL-2 levels,
it could also represent a myriad of proteins including IL-4, and IFN-γ. Similarly,
S2 represents the proteins that are predominantly produced by regulatory T cells.
These include TGF-β and IL-10. We consider the magnitude of these signals to be
proportional to the number of cells that produce them, and hence, S1 = ξH and
S2 = βR. The function a(t) is used to simulate recruitment of cells as a result
of antigen presentation. This function is a Gaussian-like function, starting from 0,
stays positive for some time, and returns to 0. A precise definition of a(t) is given
in Section 2.4.
The dynamics of helper T cells is described by Eq. (2.1). The second term
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on the RHS of (2.1), γ S1H(1−H)
1+cS2
, describes the immune recruitment and prolifera-
tion of helper T cells. These cells are modeled as proliferating following a logistic
growth rate. This growth is then modified by the present signals. S1 signals are
autostimulatory for helper T cells, while S2 signals are regulatory. The factor
γS1
1+cS2
multiplying the logistic growth of helper T cells reflects the effects these signals have
on helper T cell recruitment and proliferation. The multiplicative factor S1 accounts
for the autostimulatory effects of this population and (1 + cS2)
−1 accounts for the
negative effects of the regulatory signals. The second term describes the creation of
helper T cells that have originated from regulatory T cells that have lost their reg-
ulatory capabilities. Pro-inflammatory S1 signals are required for the maintenance
of regulatory T cell function. Hence, this switch from a regulatory T cell to a helper
T cell occurs when there is a lack of pro-inflammatory signals produced by helper
T cells. The final two terms of this equation model the removal of helper T cells
from the system. These cells have both a natural death rate; assumed to be the
natural death rate for all effector cells, δ0; and an adaptive death/removal rate that
is proportional to the mass action interaction with regulatory T cells, δ1.
Equation (2.2) describes the concentration of Tregs in the regulatory T cell
compartment. Regulatory proliferation and recruitment depends both on autostim-
ulatory signals from other regulatory T cells and on signals coming from immune
promoting cells. These interactions are described by the second term of Equation
(2.2). Regulatory T cells are modeled as proliferating at a logistic growth rate with
multiplicative factors, S1 and S2 indicating the presence of the co-stimulatory signals
needed to facilitate this proliferation. The term − µR
1+dS1
is the negative of the corre-
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sponding Treg switching term in Equation (2.1). Lower levels of S1 signals creates
higher rates of transition from regulatory to helper T cells while higher prevalence of
S1 helps to sustain regulatory cells and decreases the rate of transition. Regulatory
T cells have a natural death rate δ0.
2.4 Results
We begin by demonstrating that the model (2.1) – (2.2) can capture some
of the key characteristics of the immune response. After validating the model, we
proceed by considering the implications of Treg functional switching within the
model.
We begin our study by defining the term for antigen presentation, a(t). We





: x ≥ 0,






where b, c > 0. Graphs of a(t) for b = 5, c = 4 and b = 10, c = 3 are shown in Figure
2.3.
Figure 2.4 shows a simulation of (2.1)–(2.2) with b = 5, c = 4. The parameters
used in this simulation are shown in Table 2.1. These parameters are chosen to
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Figure 2.3: Antigen stimulation function, a(t), for b = 5, c = 4 and b = 10, c = 3.
demonstrate the characteristics of the model. They are not biologically motivated.
A choice of parameters that is directly tied with the biology is conducted for the
more comprehensive model described in Chapter 3. The dynamics of the simulated
system seem to be similar over across many values of b and c. In accordance with the
antigen stimulation, we identify a growth of the helper T cells peaking soon after
the peak of antigen presentation. After antigen clearance, there is a contraction
of immune cells leading to a positive steady state. These lingering helper T cells
correspond to the emergence of memory T cells. As a model of the cellular immune
process, these results agree with the expansion, contraction, and memory dynamics
seen in other mathematical models of the primary immune response [4, 58, 81].
We conclude that model, with the consideration of the new regulatory switching
mechanism, displays the expected expansion/contraction dynamics.
We now study the effects of the regulatory T cell switching. What is the con-
tribution of the µ
R
1 + kS1
term to the system? Figure 2.5 shows how the magnitude
of the Treg switching term changes over the course of simulation. The death rate
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Parameter Description Estimate
γ immune recruitment rate of helper T cells 1
c inhibitory rate of TGF-β on helper T cell
recruitment
1
µ magnitude of regulatory T cell switching
rate
9
d magnitude of dependence of Treg switching
on helper T cell signals
1
δ0 natural death rate of effector T cells 0.01
δ1 death rate of helper T cells as a result of
interaction with Tregs
0.01
ν immune recruitment rate of regulatory T
cells
1
ξ multiplicative factor of helper T cell signals 1
β multiplicative factor of regulatory T cell
signals
0.5
Table 2.1: Parameter values used in simulations of (2.1) – (2.2). Concentrations are
measured in k/mm3. Time is measured in days.
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Figure 2.4: Simulation of (2.1)–(2.2) with parameters from Table 2.1. The dynamics
of the helper T cells is shown in the solid line. Antigen presentation, a(t), with b = 4,
c = 5 is shown with a dashed line.
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Figure 2.5: A graph of the magnitude of the transition rate of regulatory T cells
due to helper T cell signals for the simulation shown in Figure 2.4.
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of Tregs due to lack of signaling gradually increases as the immune response pro-
gresses. While the antigen is present, and helper T cell levels are high, the number
of regulatory T cells is allowed to flourish in order to maintain control of the growing
helper T cell population. Once the antigen is removed from the system (day 5 in
Figure 2.5), this death rate levels out at its maximum. This new constant death
rate combined with the removal of antigen stimulus serves to gradually bring the
system into homeostasis. This variable death rate contributes to the dynamics in
two ways. First, it allows the growth rate of the Tregs to be high enough to control
the helper cells during the reaction. It allows the death rate to be high enough
after the reaction to return back to normal levels of between 5 and 10 percent of the
helper T cell population. Second, this mechanism allows for the presence of memory
helper T cells after the reaction is over.
The velocity field of the system (with a(t) ≡ 0) is shown in Figure 2.6. The
trajectories for different initial conditions are shown overlaid on the velocity field.
The general tendencies towards the steady states can be seen. Of importance here
is the ability of the system to cope with imbalances in the helper to regulatory ratio.
In cases where regulatory T cells are too numerous (upper right portion of Figure
2.6, green path), there is a markedly sharp drop in the number of regulatory T cells
due to the lack of pro-inflammatory signaling. When the ratio is extended too much
in favor of helper T cells (right portion of Figure 2.6 and black path), we see the
gradual decrease in both the regulatory T cells and helper T cell path bringing the
system to an equilibrium. If imbalances occur within a normal range (e.g. if created
through antigen stimulation), we see not only a decrease in regulatory T cells, but
30
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Figure 2.6: Velocity field of Equations (2.1)–(2.2) shown in blue. Trajectories over
the velocity field are graphed for different initial conditions: H = 0.5, R = 2 (red);
H = 2.5, R = 3 (green); H = 3, R = 1.25 (black).
also the transition of Tregs leads to an increase in the helper T cell population before
decreasing back to equilibrium (black curve). This shows that even in biologically
unbalanced situations, the switching mechanism allows excess regulatory T cells to
contribute to the growth of helper T cells, rather than restrict it. This feedback is
crucial in the stability of the system both. Biologically, this type of imbalance can
occur in a number of diseases such as HIV, autoimmune diseases, cancer [18, 32, 45].
These diseases alter the constituency of immune cells and therefore mechanisms such
as regulatory T cell stability may a crucial component of accurately modeling these
systems.
Functional Treg switching can contribute to both the stability and the mag-
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Figure 2.7: Phase portrait of helper T cells versus regulatory T cells for various
values of µ.
nitude of an immune response. Because there is little to no data on the rates at
which this switching occurs, we now try to qualitatively determine how the value
of µ should be chosen. A phase portrait of the simulations for various values of µ
is shown in Figure 2.7. The model with no regulatory switching (µ = 0), is plotted
in the dotted red line. For this model, as in the case with switching, the helper T
cell population is able to expand and contract with respect to the regulatory T cell
population. But, the final steady state of the system shows that the regulatory and
helper T cell concentrations are on the same order of magnitude. While regulatory
T cells have been shown to increase during an infection, it has also been shown
that these cells return to their normal levels post pathogen exposure [94]. Hence we
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consider the model with µ > 0 to be more biologically accurate. Figure 2.7 shows
that the main effect of µ is to affect the number of tregs produced in the course
of an immune response. For the values of µ shown, the maximum ratio of Treg to
helpers varies from 0.09 to 0.83. Biologically, we know that the concentrations of
Tregs and helper T cells should not be equal, as this would contribute to disease
development. This leads us to reject the smaller µ values that lead to such ratios.
We also know that in the course of an immune response, the number of tregs should
increase relative to their resting concentration [118]. Because these cases do not
show an increase in Tregs at the infection sight, we also reject µ = 50 and other
high values of µ which lead to a Treg to helper T cell ratio in the range of 5-10%.
To aid in choosing an appropriate value of µ, we consider the peak helper T cell
concentration produced for certain values of µ. Figure 2.8 shows a graph displaying
the peak helper T cell concentration as a function of µ for µ in the range [0 20].
For these parameter values, the maximal immune response is obtained when µ = 9.
Consistent with what was seen in Figure 2.7, Treg switching can either contribute to
the strength of an immune response or diminish it. Assuming that the natural goal
of the body is to maximize the strength of the immune response, this model shows
that the order of magnitude of the µ parameter should be 9. But does this imply a
reasonable Treg to helper T cell ratio? For the value µ = 9, the maximal ratio of
Tregs to helpers is 44.9%. Though we do not have biological experiments to know
what this ratio should be in the periphery, as previously discussed, it should be
greater than 10% and less than 100%. This value falls in the middle of the plausible
range and hence we consider µ = 9 to be an acceptable choice.
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Figure 2.8: Maximum helper T cell concentration as a function of µ.
Finally, we simulate conditions that reflect the experimental setup of [37].
Here we simulate the addition regulatory T cells into an otherwise T cell deficient
environment. These characteristics arise when the model is considered with initial
conditions H = 0 and R 6= 0. Figure 2.9 shows the results of thi simulation. As in
the experiments of [37], simulations show the regulatory T cell population decreasing
due to conversion to helper T cells. In finite time, a balance of signals is achieved
and the populations achieve a non-zero equilibrium. This property of the model has
not been seen in past models of the cellular immune system. It shows that even in
the case of extreme imbalances of initial conditions, this Treg switching mechanism
serves as a stabilizing mechanism and the system is able to recover to a biologically
favorable state.
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(a) Helper T cell deficient simulation: helper T
cells.
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(b) Helper T cell deficient simulation: regula-
tory T cells.
Figure 2.9: Simulation of the initially helper T cell deficient system with initial
conditions H = 0, R = 3.
2.5 Discussion
In this chapter, we developed a model of immune regulation and differentia-
tion that is based on the biological study of [94]. The model considers helper T
cells and regulatory T cells and highlights two recently accepted biological mecha-
nisms: active suppression of helper T cells by regulatory T cells and the transition
of regulatory T cells into helper T cells. Active suppression by regulatory T cells
was shown to be a plausible mechanism of immune contraction as negative feedback
provided by these cells was able to control immune expansion and return the system
to homeostasis. Inclusion of the switching mechanism was shown to not disturb
the expansion/contraction dynamics commonly displayed in immune models. This
mechanism was shown to increase the robustness of the system, allowing for recovery
from an imbalanced or even helper T cell deficient system.
We characterized the affects of Treg switching on the peak magnitude of the
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immune response and identified the order of magnitude of the switching parameter,
µ, that appears to be consistent with both the magnitude of the concentrations
involved in an immune response and the ratio of Tregs to helper T cells.
The model can be extended in many directions. First, one can separate the
dynamics between the lymph nodes and the site of infection. Under these conditions,
one can investigate hypotheses such as those stating that only antigen induced Tregs
in the periphery have the ability to become immuno stimulatory. Another extension
will be to consider the case where only a certain percentage of Tregs may differentiate
sideways. In Chapter 3, we use the knowledge gathered here to extend our study
on the primary immune response by including both active T cell suppression and




Modeling Adaptive Regulation with Regulatory T Cell Switching
3.1 Introduction
While the initial phases of T cell expansion are well understood (see [79]), the
final contraction phase of the immune response is not. This contraction phase is
crucial in bringing the immune system back to a stable state. Such a contraction
must happen quickly to prevent damage to healthy cells and to prepare the sys-
tem for future challenges. Hence, cell-mediated immune responses must be closely
regulated following any antigenic stimulation.
Several key characteristics of the immune response should be considered when
developing a model of these processes. Mercado et al. showed that T cell contrac-
tion and expansion were determined after 24 hours of exposure to a foreign antigen
[75]. Kaech supported this by demonstrating that even with very short duration of
exposure to antigen, cytotoxic T cells will divide 7 – 10 times even after the antigen
is removed [57]. Van Stipdonk observed that upon 20 hours of stimulation, näıve
CD8+ T cells were able to carry out extensive proliferation and cytotoxic activity,
characteristic of a fully developed immune response [108]. When combined together,
experimental evidence suggests that the T cell response is mostly dictated in the
first hours of antigen exposure and is therefore largely insensitive to the later charac-
teristics of antigen exposure. A conclusion of these observations is that upon initial
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activation by antigen exposure, T cells enter into an antigen-independent prolifera-
tion phase, known as a “T cell program”. Mathematically, this has led to approaches
rooted in a concept of T cell expansion wherein T cells enter a predetermined pro-
gram where they divide for either a specified period of time or specific number of
divisions [4, 58, 116]. The T cell response is also characterized in that it is robust to
the precursor frequencies of antigen-specific näıve T cells. This is demonstrated by
Badovinac et al. who showed that a 10,000-fold difference in antigen-specific T cell
concentrations led to a mere 13-fold difference in peak of the CD8+ T cell response
[7]. Mathematical models that address this data have been developed by Kim, Levy,
and Lee [58, 59, 61] and will be discussed in further detail in Sections 3.1.1 and 3.2.
In this chapter, we construct mathematical models of the primary immune
response taking into account the following biological observations:
• The T cell response is mostly determined in the first hours of antigen presen-
tation [57, 75, 108].
• The T cell response is insensitive to precursor T cell frequencies [7].
• Regulatory T cells are the mechanism of contraction following pathogen clear-
ance (see Section 2.2.1).
• Regulatory T cells have the ability to change their functionality and become
immune promoting helper T cells [94].
In Section 3.1.1, we examine the characteristics of both division-based and time-
based T cell programs and argue why neither hypotheses can account for the in-
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herent robustness of the T cell response with respect to variations in the precursor
frequency. In [58] and [59], Kim, Levy and Lee present a mathematical model of the
immune response including adaptive regulatory T cells and show these cells they
may play a crucial role in inducing a timely and robust contraction of the T cell
response. In Section 3.2, we extend the models developed in [59] in light of the
data presented in Chapter 2 to consider the affects of functional regulatory T cell
switching. In 3.2.1, we define the related concept of immunodominance and discuss
an extension of the immunodominance model of [59]. In Section 3.3, simulations of
this model are shown and its robustness is demonstrated. Concluding remarks are
given in Section 3.4.
3.1.1 T Cell Programs
Initial models of the dynamics of the immune response were based on predator-
prey type dynamics wherein immune cells acted as predators and pathogens served
the roll of the prey (see [2] for example). These models are able to generate some of
the general features of the immune response such as expansion/contraction dynam-
ics. However, they fail to exhibit some key experimentally-obtained features of the
immune response. For example, these models do not show robustness to precursor
frequencies or the ability to maintain an immune response after pathogen clearance.
The concept of a T cell program has been put forth to address the issue of anti-
gen independence. In general, models developed under this paradigm describe the
cell-mediated immune response as having a period of antigen-independent prolifera-
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tion and a period of antigen-dependent proliferation that is followed by contraction
that is determined by one of the theories mentioned in Section 2.2.1 (time-based,
division-based, active suppression). These models are more consistent with ex-
perimental data concerning the antigen independent characteristics of the immune
response shown in [57], [75] and [108].
In [4], Antia et al. develop models of the primary T cell response to acute infec-
tions. First, a model of antigen-independent T cell proliferation is considered. The
T cell response is modeled as follows: upon initial antigen stimulation, CD8+ T cells
progress through a fixed program of expansion, contraction and differentiation into
memory cells. Further exposure to antigen does not alter the response. An alterna-
tive paradigm developed in this paper is one in which stimulated T cells undergo a
short period of antigen-dependent expansion before entering an antigen-independent
program. This model exhibits the expected basic expansion/contraction dynamics.
This choice of technique for modeling antigen-independence has two noteworthy con-
sequences. First, the model shows the ability to continue an immune response after
removal of the antigen. This aligns with the experimental data of Kaech, Mercado
and van Stipdonk [57, 75, 108]. However, as noted in [58], the antigen-dependent and
antigen-independent parts of Antia’s 2003 model occur in the opposite order of the
more common notion that a developmental program precedes antigen-dependent
proliferation as suggested in [57]. Furthermore, this arrangement of proliferation
implies that the cell programming process takes approximately 2.5 days which con-
tradicts van Stipdonk who proposes a 20 hour programming period [109, 108] and
the 24 hour programming period proposed by Mercado [75]. Second, as observed
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by Kim et. al., a fixed program of expansion predicts that the magnitude of the
response is directly proportional to the initial number of antigen-specific precursor
T cells [58]. Hence, the Antia model contradicts the findings of Badovinac, which
show that the magnitude of the immune response is largely insensitive to T cell
precursor frequencies [7].
Wodarz and Thomsen developed a mathematical model in which antigen-
independent cell divisions occur prior to antigen-dependent proliferation. In this
model, activated T cells undergo a fixed number of divisions before differentiating
into effectors and then into memory cells [116]. If infection persists, memory cells
recycle back into the effector state and enter another round of divisions, repeating
the program as many times as necessary. Consistent with experimental studies, the
study of this model concluded that the optimal fixed division program entails 7 –
10 divisions. However, contrary to experimental studies, cells cannot return to the
effector state without committing to the entirety of the T cell program. This could
lead to a protracted response possibly leading to damage to healthy cells.
Models derived under either time or division-based proliferation programs typ-
ically generate robust responses to antigen availability but scale with respect to
precursor frequencies. As an alternative to these approaches, Kim et al. develop
a model under the hypothesis that the contraction of the immune response is gov-
erned by a preprogrammed initial activation phase that is augmented by adaptive
regulatory mechanisms [58]. The authors present a model where T cell contraction
is not uniquely determined by a predetermined program, but comes about as the
result of negative feedback loops through interactions with regulatory T cells. In
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this model, CTLs enter a “minimal development program” in which they commit
to proliferation. This program initiates upon activation by antigen presenting cells
and represents the antigen-independent portion of the immune response. After the
minimal development program, if a cell receives further stimulation, it undergoes
singular cell division, representing the antigen-dependent portion of the process.
When compared with both the cell-division and time-based predetermined T
cell programs, the model of Kim et. al. displays a robustness to T cell precursor
frequencies that is more consistent with the experimental studies of [7]. A 4 order
of magnitude difference between näıve T cell frequencies reduces to a three order
of magnitude difference in effector T cell peaks. The reduction in scaling is much
closer to experiments than the direct scaling which is inherent to autonomous T cell
programs. Hence, the model of Kim et. al demonstrated that such an approach
produces a primary T cell response that is robust to both antigen stimulation and
precursor frequencies.
In [58], the regulation of cytotoxic T cells was considered. The T cell pop-
ulation was not divided into helper T cells and CTLs. The model was extended
in [59] and [61] to consider the regulation of helper and cytotoxic cells separately.
This added measure of biological accuracy is consistent with our current theory of
immune regulation and amenable to a consideration of regulatory T cell switching.
Hence, our starting point is the model of [59] which we extend to incorporate our
work on regulatory T cell stability developed in Chapter 2 into more comprehensive
models of regulation.
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3.2 A Mathematical Model of Adaptive Regulation with Treg Switch-
ing
The work presented here is based on the “Extended model of adaptive reg-
ulation: helper and killer T cells” presented in [59]. In this model, the immune
reaction is modeled as a system of delay differential equations. The delay is derived
from the notion that upon activation, a cell will spend a specified amount of time
solely devoted to mitosis (cell division) before it can properly execute its functions.
This model also considers the production and consumption of the pro-inflammatory
cytokine IL-2. Consistent with current knowledge of T cell lineage, regulatory T
cells differentiate from the helper T cell population and are able to suppress both
helper and cytotoxic T cells [94]. The model is consistent with the theory of ac-
tive suppression, displays many inherent immune characteristics (antigen and T cell
precursor-independence), and thus provides an excellent framework within which to
consider Treg switching. In our work, we use the work of [59] as the basic model to
which we add terms to allow for regulatory T cell switching. Our model is described
as follows (illustrated in Figure 3.1):
1. Upon encountering antigen, a(t), immature APCs, A0(t), become mature
APCs, A1(t), and migrate to the lymph node.
2. Näıve helper and cytotoxic T cells (H0(t) and K0(t), respectively) residing in
the lymph nodes encounter mature APCs and enter a minimal developmental
program in which they divide m1 or m2 times respectively.
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3. Mature helper and cytotoxic T cells (H(t) and K(t), respectively) both secrete
the positive growth signal IL-2, denoted P (t).
4. Mature helper and cytotoxic T cells that have completed the minimal devel-
opmental program become effector cells that continue dividing upon further
antigenic stimulation. This antigen dependent proliferation occurs in response
to interactions with APCs for helper T cells and in response to IL-2 consump-
tion for cytotoxic T cells.
5. In response to antigenic stimulation, some proportion of helper T cells further
differentiate into Tregs, R(t).
6. Regulatory T cells enact their feedback on the system by:
• suppressing mature helper and cytotoxic T cells,
• proliferating after consuming free positive growth signal,
• transitioning back into the helper T cells at a rate that depends on the
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Our model of adaptive regulation with regulatory T cell switching is given by
the following equations:
Ȧ0(t) = sA − d0A0 − a(t)A0(t) (3.1)
Ȧ1(t) = a(t)A0(t) − d1A1(t) (3.2)
Ḣ0(t) = sH − δ0H0(t) − kA1(t)H0(t) (3.3)
Ḣ(t) = 2m1kA1(t − σ1)H0(t − σ1) − kA1(t)H(t) + 2kA1(t − ρ1)H(t − ρ1)
+ µ2
R(t)
1 + dP (t)
− (δH + r)H(t) − kR(t)H(t) (3.4)
K̇0(t) = sK − δ0K0( ) − kA1(t)K0(t) (3.5)
K̇(t) = 2m2kA1(t − σ2)K0(t − σ2) − kP (t)K(t) + 2kP (t − ρ2)K(t − ρ2)
− δKK(t) − kR(t)K(t) (3.6)
Ṗ (t) = r1H(t) + r2K(t) − δP P (t) − kP (t)K(t) − kP (t)R(t) (3.7)




A0 is the concentration of APCs at the site of infection and A1 is the concen-
tration of APCs that have matured, started to present target antigen, and migrated
to the lymph node. The variable H0 is the concentration of näıve helper T cells,
H is the concentration of mature helper T cells, K0 is the concentration of näıve
cytotoxic T cells, K is the concentration of mature cytotoxic cells, and R is the
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Ȧ1(t) = a(t)A0(t) − d1A1(t) (3.2)
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Figure 3.1: Diagram of the adaptive regulation with T cell switching model. The
compartments are represented as follows: A0: immature APCs, A1: mature APCs,
H0: näıve helper T cells, H: mature helper T cells, K0: näıve effector T cells, K:
mature cytotoxic T cells, P : IL-2 cytokine, and R: regulatory T cells. Note that
each compartment has an associated death rate, which is not represented in the
diagram.
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Figure 3.1: Diagram of the adaptive regulation with T cell switching model. The
compartments are represented as follows: A0: immature APCs, A1: mature APCs,
H0: näıve helper T cells, H: mature h lper T cells, K0: näıve effector T cells, K:
mature cytotoxic T cells, P : IL-2 cytokine, and R: regulatory T cells. Note that
each compartment has an associated death rate, which is not represented in the
diagram.
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Our model of adaptive regulation with regulatory T cell switching is thus given
by the following equations:
Ȧ0(t) = sA − d0A0 − a(t)A0(t), (3.1)
Ȧ1(t) = a(t)A0(t)− d1A1(t), (3.2)
Ḣ0(t) = sH − δ0H0(t)− kA1(t)H0(t), (3.3)
Ḣ(t) = 2m1kA1(t− σ1)H0(t− σ1)− kA1(t)H(t) + 2kA1(t− ρ1)H(t− ρ1)
+ µ
R(t)
1 + dP (t)
− (δH + r)H(t)− kR(t)H(t), (3.4)
K̇0(t) = sK − δ0K0(t)− kA1(t)K0(t), (3.5)
K̇(t) = 2m2kA1(t− σ2)K0(t− σ2)− kEP (t)K(t) + 2kP (t− ρ2)K(t− ρ2)
− δKK(t)− kR(t)K(t), (3.6)
Ṗ (t) = r1H(t) + r2K(t)− δPP (t)− kP (t)K(t)− kP (t)R(t), (3.7)
Ṙ(t) = rH(t) + 2kP (t− ρ1)R(t− ρ1)− kP (t)R(t)
− µ R(t)
1 + dP (t)
− δHR(t). (3.8)
A0 is the concentration of APCs at the site of infection and A1 is the con-
centration of APCs that have matured and begun presenting antigen in the lymph
node. The variable H0 is the concentration of näıve helper T cells. H is the con-
centration of mature helper T cells. K0 is the concentration of näıve cytotoxic T
cells, K is the concentration of mature cytotoxic cells, and R is the concentration
of Tregs. The growth signal, P , is the concentration of interleukin-2.
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Equation (3.1) describes the immature APCs maintained throughout the body.
There is a constant supply rate, sA and proportional death rate, d0. The invasion
by an immunogen is represented by the rate, a(t) defined by (2.3), with which the
immunogen stimulates immature APCs to become mature APCs. The equation
governing mature APCs in the lymph node is given by (3.2). The source of these
cells is immature APCs that have been stimulated by antigen contact. These cells
have a natural death rate of d1.
Näıve T cell populations are described by Equations (3.3) and (3.5). Helper
and cytotoxic T cells have a supply rate of sH and sK , respectively, and die at a
proportional rate δ0. Each of these populations mature at a rate proportional to
their mass action interactions with mature APCs.
Equation (3.4) characterizes the mature helper T cell population. The first
term gives the rate at which activated näıve helper T cells become mature upon
completion of the minimal developmental program of m1 cell divisions. The duration
of this minimal developmental program is signified by the time delay σ1. The second
and third terms correspond to antigen dependent proliferation and represents the
rate at which these cells are stimulated by mature APCs for further division. The
time delay of ρ1 is the duration of one CD4+ cell division. The fourth term describes
the influx of helper T cells that have originated from regulatory T cells that have
lost their suppressive capabilities. This term is one of the additions to the model
of [59] due to the assumed Treg switching. Mature helper cells are removed from
the system by three methods: natural death at rate δH , differentiation into Tregs at
rate r, or by suppression due to interactions with Tregs.
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Equation (3.6) governs mature CTLs. The first term of this equation gives
the rate at which activated näıve CD8+ T cells enter the mature population after
finishing the minimal developmental program of m2 cell divisions. The duration
of the minimal developmental program is given by the time delay σ2. The second
term is the rate at which these cells are stimulated by IL-2 for further division,
and the third term is the rate at which cells reenter the mature CTL population
after dividing once in the time period ρ2. CTLs die naturally at a rate δK and are
suppressed by Tregs.
The dynamics of IL-2 concentration are given by Equation (3.7). This cytokine
is produced by mature helper and cytotoxic T cells at rates r1 and r2 respectively.
The cytokine has a proportional decay rate, δP . The final terms of this equation
describe the rates at which IL-2 is consumed by mature CTLs and Tregs.
The final equation, (3.8), describes the regulatory T cell compartment. The
first term is the rate at which mature helper T cells differentiate into Tregs. The
second and third terms describe the rate at which Tregs are stimulated by IL-2 for
further division. Upon stimulation, Tregs are removed from the system at time,
t, divide and return with a delay of ρ1. The fourth term describes the rate of
loss of regulatory function. As described in Section 2.3, this rate is dependent
on the availability of IL-2. Lower values of P (t) create higher rates of transition
from regulatory to helper T cells while higher prevalence of P (t) helps to sustain
regulatory cells and decreases the rate of transition. Tregs also have a natural death
rate δH .
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3.2.1 A Model of Immunodominance with Treg Switching
In response to multiple epitopes (antigen molecules that the immune system
recognizes), the immune response organizes into hierarchies in which the most dom-
inant epitope elicits the most prominent T cell response. This phenomenon is
known as immunodominance. If the most dominant epitope is removed, the sec-
ond most dominant response may expand to compensate. Immunodominance hi-
erarchies might change during subsequent presentations of the same antigen. The
precise mechanisms of immunodominance are not well understood and there are two
general schools of thought. Either T cells passively compete for resources (such as
growth factors, access to APCs, etc.), or T cells actively suppress each other, leading
to a structured response against the dominant epitopes [61].
There have been a number of mathematical models of immunodominance. For
instance, the model developed in [81] shows that for an antigenically homogeneous
virus population, there will be complete immunodominance, in which the immune
system responds to only one epitope. This model also predicts that multiple immune
responses against different epitopes can coexist. Kim et al. demonstrate how their
model can be adapted to describe the phenomenon of immunodominance in [59]. A
number of different scenarios are tested including, but not limited to, chronic antigen
stimulation, knocking out dominant epitopes, and secondary immune responses.
These simulations led to the conclusion that the determination of which epitope
will result in the dominant T cell response depends on both precursor frequency
and T cell reactivity to each epitope. Following [59], we extend our model (3.1) –
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(3.8) to account for n distinct immune epitopes. This leads to the following model:
Ȧ0(t) = sA − d0A0 − a(t)A0(t), (3.9)
Ȧ1(t) = a(t)A0(t)− d1A1(t), (3.10)
Ḣ0i (t) = sH,i − δ0H0i (t)− kiA1(t)H0i (t), (3.11)
Ḣi(t) = 2




− (δH + r)Hi(t)− kRtotal(t)Hi(t), (3.12)
K̇0i (t) = sK,i − δ0K0i (t)− kiA1(t)K0i (t), (3.13)
K̇i(t) = 2
m2kiA1(t− σ2)K0i (t− σ2)− kEP (t)Ki(t) + 2kiP (t− ρ2)Ki(t− ρ2)
− δKKi(t)− kRtotal(t)Ki(t), (3.14)
Ṗ (t) = r1Htotal(t) + r2Ktotal(t)− δPP (t)− kP (t)Ktotal(t)− kP (t)Rtotal(t), (3.15)
Ṙi(t) = rHi(t) + 2kP (t− ρ1)Ri(t− ρ1)− kP (t)Ri(t)
− µ Ri(t)
1 + dP (t)
− δHRi(t). (3.16)
Here, we consider T cell clones i = 1...n. For näıve T cells, mature T cells,
and regulatory T cells, there is a separate equation for each epitope, denoted by
the subscript i. Each clone has an individual kinetic rate, ki. Although regulatory
T cells are recruited with respect to a specific epitope, their suppressive activity is
assumed not to be antigen specific. Thus, the suppressive terms are proportional




of the epitope of origin. Similarly, IL-2 is not epitope specific in its actions and the
production of this cytokine is proportional to the total number of IL-2 producing
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cells in the system and grows with respect to Htotal =
n∑
i=1




3.3 Results and Simulations
We solve equations (3.1) – (3.8) numerically using Matlab’s DDE solver, dde23.
Parameter values for the model are given in Table 3.1. Most parameters were ob-
tained from [59] to which we refer for full justification. The parameters for µ and d
are approximated based on their contribution to the dynamics of the system. Figure
3.2 shows the evolution of the APC and CTL populations. Figure 3.2(a) demon-
strates that immature APCs are able to mature within approximately 2.5 days of
the initiation of the immune response. Consistent with the biological findings of [75]
and [108], the entire näıve CTL population is recruited to participate in the immune
response within 1 day of the start of simulation. Also, coinciding with experimental
measurements showing that the T cell response peaks at 8 days after initiation [31],
the simulation also demonstrates a peak CTL response at day 8.
We consider the consequences of positive and negative signals received by
CTLs in Figure 3.3. Here we study how cytotoxic T cells behave relative to IL-2
and regulatory T cells. Initially, IL-2 levels rise due to the increase in the number of
mature helper T cells (not shown). Further divisions past the minimal developmen-
tal program require the consumption of IL-2. Hence, as CTLs complete the minimal
development program, they begin to consume IL-2, leading to a decrease in IL-2 con-
centration. Corresponding to the peak CTL response is the initiation of regulatory
T cell proliferation. This rise in Tregs contributes to ending the CTL response in
51
Description Estimate
A0(0) Initial concentration of immature APCs 10
H0(0) Initial concentration of näıve CD4+ T cells 0.06
K0(0) Initial concentration of näıve CD8+ T cells 0.04
sA Supply rate of immature APCs 0.3
d0 Death rate of immature APCs 0.03
b Duration of antigen availability 10
c Level of APC stimulation 2
d1 Death rate of mature APCs 0.8
sH Supply rate of näıve CD4+ T cells 0.0018
sE Supply rate of näıve CD8+ T cells 0.0012
k Kinetic coefficient 5
δ0 Death rate of näıve T cells 0.03
δH Death rate of mature helper T cells 0.23
δK Death rate of mature cytotoxic T cells 0.4
m1, m2
Number of divisions in minimal
development program for helper T cells 2, 7
and CTLs, respectively
σH , σK
Duration of minimal developmental program 1.46, 4
for helper T cells and CTLs, respectively
ρH , ρK
Duration of one T cell division 11/24, 1/3
for helper T cells and Tregs, respectively
kE kinetic coefficient for CTL-Treg interactions 20
r1 Rate of IL-2 secretion by mature helper T cells 10
r2 Rate of IL-2 secretion by mature CTLs 1
δP Decay rate of free IL-2 5.5
r
Rate of differentiation of helper T cells
into regulatory T cells 0.02
d magnitude of dependence of Treg switching on IL-2 10
µ Rate of regulatory T cell switching 5
Table 3.1: Estimates of parameters for model (3.1) – (3.8). Concentrations are
measured in k/mm3. Time is measured in days. Initial conditions not explicitly
given in the table are zero.
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(a) Immature and mature APCs.





















100 ! naïve CTLs
mature CTLs
Student Version of MATLAB
(b) Näıve and mature CTLs
Figure 3.2: Simulation of (3.1) – (3.8) with parameters given in Table 3.1. The
time evolution of antigen presenting cells and cytotoxic T cells are shown in Figures
3.2(a) and 3.2(b), respectively.
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Figure 3.3: Time evolution of cytotoxic T cells, regulatory T cells and IL-2 in a
simulation of (3.1) – (3.8) with parameters given in Table 3.1.
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two ways. First, direct contact between Tregs and CTLs removes CTLs from the
system. Second, because both Tregs and CTLs consume IL-2 as part of their divi-
sion processes, competition for this cytokine reduces its availability, hindering the
ability of CTLs to continue dividing.
We simulate the experiments of Badovinac in Figure 3.4. Here, we vary the
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Figure 3.4: Numerical experiment reflecting the biological experiments performed
by Badovinac in [7]. The maximal mature CTL concentration is considered as a
function of the initial näıve CTL concentration.
concentration of initial näıve CTLs, K0(0), and note the maximum mature CTL
concentration during the simulation. Similar to Badovinac, we perform this simula-
tion over a group of initial concentrations ranging over 4 orders of magnitude. Our
results show that over this range of initial concentrations, there is a change in peak
response that varies by 1 order of magnitude. This is on par with the experimental
results showing that a 10,000-fold change initial conditions led to a 13-fold change in
peak response [7]. This is an improvement over the results of [59] in which a range
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of 4 magnitudes in initial conditions led to a change of 3 orders of magnitude in
peak response. We conclude that in comparison to the models presented in [59], the
inclusion of Treg switching increases the system’s robustness to initial conditions.
To study the impact of the regulatory T cell switching parameter, µ, on the
dynamics of the system, we follow the techniques used to study equations (2.1) –
(2.2) in Section 2.4. These results are shown in Figure 3.5. In Figure 3.5(a), we
show the maximal number of CTLs as a function of µ. Unlike the results shown in
Figure 2.8, this function of µ appears to be monotonic. However, it is clear that
there is a more significant change in peak CTLs per change in µ for values of µ less
than 5. We also consider the maximal ratio of Tregs to CTLs when choosing a value
for µ. In Figure 3.5(b), we show the maximal Treg to CTL ratio as a function of
µ. As discussed in Chapter 2, we expect this ratio to be in the range 0.1 – 1. We
concentrate on ratios that lie in the center of this range and hence consider µ values
between 4 and 10 (corresponding to ratios between .6 and .41).
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(a) Maximum cytotoxic T cell concentration as
a function of µ.
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(b) Maximum ratio of Treg to CTL concentra-
tion as a function of µ.
Figure 3.5: Graph depicting how the Treg switching rate, µ, affects the maximum
CTL concentration (Figure 3.5(a)) and Maximum Treg to CTL ratio (Figure 3.5(b)).
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3.3.1 Simulations of Immunodominace
We simulate equations (3.9) – (3.16) to consider multiple T cell clones (epi-
topes) responding to the same target at once. Each epitope is characterized by its
reactivity to the target antigen, ki, and its initial näıve CTL concentration, K
0
i (0).
The theory of immunodominance states that when faced with multiple epitopes, the
immune system will primarily respond in accordance with a dominant epitope. If
the most dominant epitope is removed (the so-called knock out experiment), then
it is possible to have greater expansion of the less dominant epitopes to compensate
for the missing epitope.
We simulate knock out experiments in Figures 3.6 and 3.7. The immune
response to multiple clones is simulated by varying the initial CTL concentrations
of the clones (Figure 3.6) or the reactivities (Figure 3.7). Epitopes are then “knocked
out” one by one following the order of their dominance.
In Figure 3.6, we simulate four T cell clones, each with equal reactivities, ki =
20 and initial concentrations: K01(0) = 0.04, K
0
2(0) = 0.01, K
0
3(0) = 2.5× 10−3, and
K04(0) = 6.25× 10−4. Figure 3.6(a) shows a simulated immune response to all four
clones. The response falls into a hierarchy based on the initial T cell concentration
with Clone 1 remaining most dominant and Clone 4 remaining the least dominant.
Figure 3.6(b) shows the result of a single knock out, in which Clone 1 is no longer a
part of the simulation. Again, the immune response falls into a hierarchy dependent
on initial concentration. Of interest is the fact that the response to Clone 2 almost
quadruples when compared to the response elicited by Clone 2 in Figure 3.6(a).
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(a) All four clones: Clones 1,2,3 and 4.
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(b) Single knock out: Clones 2,3 and 4.
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(c) Double knock out: Clones 3 and 4.
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(d) Triple knock out: Clone 4, alone.
Figure 3.6: Simulated knockout experiment for four T cell clones. Each clone has
equal reactivity, ki = 20. Initial concentrations are: K
0
1(0) = 0.04, K
0
2(0) = 0.01,
K03(0) = 2.5× 10−3, and K04(0) = 6.25× 10−4.
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(a) All four clones: Clones 1,2,3 and 4.
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(b) Single knock out: Clones 2,3 and 4.
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(c) Double knock out: Clones 3 and 4.
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(d) Triple knock out: Clone 4, alone.
Figure 3.7: Simulated knockout experiment for four T cell clones. Each clone has
equal initial concentration, K0i (0) = 0.01. Reactivities for clones are: k1 = 40,
k2 = 20, k3 = 10, k4 = 5.
Despite the an initial concentration four times less that Clone 1, if Clone 1 is absent,
the response to Clone 2 is able to compensate and produce a robust response similar
in both timing and magnitude to the response garnered by Clone 1 in Figure 3.6(a).
Similarly, if Clones 1 and 2 are removed, Clone 3 is able to compensate with a
10-fold increase in response in Figure 3.6(c) when compared to Figure 3.6(a). For
Clone 4, when Clones 1,2 and 3 are removed, the response is approximately 25 times
stronger in Figure 3.6(d) when compared to 3.6(a).
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Figure 3.7 shows simulations for a knockout experiment in which each epitope
has the same initial concentration, K0i (0) = 0.01 and varying reactivities of k1 = 40,
k2 = 20, k3 = 10, and k4 = 5. We want to consider how this variation in reactivities
effects knock out experiments. Figure 3.7(a) shows a simulated immune response to
all four clones. As expected, the response falls into a hierarchy based on the initial
T cell concentration with Clone 1 being the most dominant and Clone 4 being the
least. A single knock out of Clone 1 is simulated in Figure 3.7(b). Different than
the knock out simulation in Figure 3.6(a), there is no clear compensation from any
of the remaining clones. Reactions to Clones 2, 3, and 4 are minimally increased
in Figure 3.7(b) than in Figure 3.7(a). Similar results are seen in Clones 3 and 4
when Clones 1 and 2 are removed (Figure 3.7(c)). Interestingly, the triple knock out
simulation does lead to Clone 4 expanding to compensate for the missing epitopes.
In fact, the response to Clone 4 alone (Figure 3.7(d)) is stronger than the response to
all four clones (Figure 3.7(a)). This suggests that, in the case of varying reactivities,
the relations that define immunodominant hierarchies may be more complex than
the linear scaling suggested in [59].
We continue our study of the effects of Treg switching on immunodominance
in Figure 3.8. As in Figure 3.6, we consider again the knock out experiment with
equal reactivities and varying initial T cell concentrations. To characterize the effects
of Treg switching, we consider the same knock out experiments for different Treg
switching magnitudes (µ = 2, µ = 4, and µ = 6). As expected from our previous
study, increasing the value of µ increases the magnitude of the peak response of
CTLs. Also, for each value of µ considered, there is significant expansion of less
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(a) All four clones. µ = 2.
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(b) All four clones. µ = 4
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(c) All four clones. µ = 6
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(d) Single knock out. µ = 2.
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(e) Single knock out. µ = 4
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(f) Single knock out. µ = 6
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(g) Double knock out. µ = 2.
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(h) Double knock out. µ = 4
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(i) Double knock out. µ = 6
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(j) Triple knock out. µ = 2.
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(k) Triple knock out. µ = 4
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(l) Triple knock out. µ = 6
Figure 3.8: Simulated knockout experiment for four T cell clones. Each clone has
equal reactivity, ki = 20. Initial concentrations are: K
0
1(0) = 0.04, K
0
2(0) = 0.01,
K03(0) = 2.5 × 10−3, and K04(0) = 6.25 × 10−4. Simulations are shown for µ = 2
(left), µ = 4 (center), and µ = 6 (right).
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dominant epitopes to compensate for the removal of more dominant epitopes. We
take a closer look at the effects of µ on the ability of T cell clones to expand in such
an experiment in Table 3.2. Here, for each clone and value of µ, we consider the peak
CTL concentration when that clone is the most dominant epitope. We then divide
by the peak response of the same clone when it is the least dominant epitope. We
term this the “multiplicative expansion factor”. This factor characterizes the ability
of a clone to expand and compensate upon becoming the most dominant epitope.
As expected, comparing values across the columns of Table 3.2 shows that less
dominant epitopes have a greater capacity to compensate for knocked out epitopes.
Comparing values down each column characterizes how µ affects the ability of a
particular clone to expand. It is interesting to note that for the same clone, µ
appear to increase the ability of the T cell clone to expand. For example, Clone 4
is capable of a larger expansion when µ = 6 when compared to its expansion when
µ = 2.
Multiplicative Expansion Factor
µ Clone 2 Clone 3 Clone 4
2 3.19 10.27 33.05
4 3.25 10.69 34.68
6 3.31 11.08 36.24
Table 3.2: Multiplicative expansion factors for the simulations shown in Figure 3.8.
We now study the effects of Treg switching in the case of varying cell reactiv-
ities. The results are shown in Figure 3.9. We consider knock out experiments for
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different Treg switching magnitudes (µ = 2, µ = 4, and µ = 6) and Clones 1 – 4
with reactivities k1 = 40, k2 = 20, k3 = 10, and k4 = 5, respectively. As expected
from our previous study, the effects of removing a clone are minimal for all but the
triple knock out simulation. The multiplicative expansion factor for these simula-
tions is given in Table 3.3. The multiplicative factors for Clones 2 and 3 indicate
that little immune compensation takes place during these simulations. In particular,
for µ = 2 and µ = 4, the expansion factor of less than 1 implies that the response
to Clone 2 decreases in response to removing Clone 1. However, consistent with
the results shown in Table 3.2, increasing µ also increases the expansion factor of a
clone, although not as significantly as in the cases shown in Table 3.2.
Multiplicative Expansion Factor
µ Clone 2 Clone 3 Clone 4
2 0.98 1.07 1.53
4 0.99 1.10 1.65
6 1.00 1.14 1.80
Table 3.3: Multiplicative expansion factors for the simulations shown in Figure 3.9.
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(a) All four clones. µ = 2.
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(b) All four clones. µ = 4






























Student Version of MATLAB
(c) All four clones. µ = 6
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(d) Single knock out. µ = 2.
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(e) Single knock out. µ = 4
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(f) Single knock out. µ = 6
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(g) Double knock out. µ = 2.
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(h) Double knock out. µ = 4
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(i) Double knock out. µ = 6
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(j) Triple knock out. µ = 2.
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(k) Triple knock out. µ = 4



























Student Version of MATLAB
(l) Triple knock out. µ = 6
Figure 3.9: Simulated knockout experiment for four T cell clones. Each clone has
equal initial concentration, K0i (0) = 0.01. Reactivities for clones are: k1 = 40,
k2 = 20, k3 = 10, k4 = 5. Simulations are shown for µ = 2 (left), µ = 4 (ce ter),
and µ = 6 (right).
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3.4 Discussion
In this chapter, we extended the work presented in Chapter 2 concerning im-
mune regulation and regulatory T cell switching. In this work, we added a mecha-
nism of Treg switching to the DDE model of [59]. The basic principles of regulatory
T cell switching described in Chapter 2 were shown to hold within the context of
this more complex model and the addition of this mechanism was shown to improve
certain aspects of the immune response studied in [59]. An improvement of this
model over past models of the immune response was seen when considering how
the immune response scales with respect to initial T cell concentrations. Consistent
with biological experiments, varying initial T cell concentrations over 4 orders of
magnitude led to a change in the peak immune response that varied by 1 order of
magnitude. Also, consistent with results found in Chapter 2, we were also able to
identify a plausible range for the rate of Treg switching, µ. Further experiments on
the rates of Treg switching could contribute to obtaining a more accurate approxi-
mation of this value.
This model was also used to study the phenomena of immunodominance. Im-
mune responses to multiple epitopes were shown to be able to coexist. Although the
response to the most dominant epitope was shown to suppress the response to other
epitopes, this model does not exhibit the winner-take-all dynamic that is seen in
some mathematical models of immunodominance (see [81]). Knock out experiments
were numerically simulated in two scenarios; one in which T cell clones vary in their
initial concentrations and another in which they vary in cell reactivities. Immune
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compensation of one epitope in response to the removal of a more dominant epitope
was seen in the case of T cell clones with varied initial concentrations. In the case of
varied cell reactivities, immune compensation was only seen in the triple knock out
simulation. This suggests that further study is required in order to determine the
relationship between cell reactivity and immunodominance hierarchies. An investi-
gation of the effects of µ on immunodominance hierarchies showed that increasing
µ not only increases the magnitude of immune response, it also increases the ability
of T cell clones to expand within the immunodominance hierarchy.
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Chapter 4
The Enhancement of Tumor Vaccine Efficacy by Immunotherapy
4.1 Introduction
Current cancer therapies predominantly focus on surgery, chemotherapy and
radiotherapy; each of which carries major side-effects. The immune system is not
always efficient in providing an adequate response to cancer, since cancer cells may
not be easy to identify, and they use various immuno-suppression techniques to avoid
the immune response (see Table 1.1). Recently, there has been an increased interest
in improving the ability of the autologous immune response to target tumors, an
approach that is generally being referred to as “immunotherapy.”
Although animal models have demonstrated that humoral mechanisms may be
relevant to immunotherapy, much of the promising work in tumor immunotherapy
has been focused on T-cell-mediated, antigen-specific vaccines. Previous research
has shown that through cellular immunotherapy, T cells can destroy large, estab-
lished tumors [91]. Over the years, researchers have taken various approaches to
tumor immunotherapy. Among these approaches are tumor cell-based vaccines,
peptide-based vaccines, virus-based vaccines, DNA-based vaccines, and dendritic
cells vaccines; each of which have met varying degrees of success at reducing or
eliminating tumors (see the review papers [33, 91] and the references therein).
This work highlights how immunotherapy might be used to overcome the
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effects of two regulatory agents exploited by cancer: regulatory T cells and the
Transforming Growth Factor (TGF)-β protein. TGF-β is a protein that controls
proliferation, cellular differentiation, and other functions in most cells. It acts as
an anti-proliferation factor in normal epithelial cells [24]. Experimental evidence
has shown that TGF-β can act as both a tumor suppressor and stimulator [86]. In
early stages, it acts directly on cancer cells to suppress their growth. As the tu-
mor progresses, TGF-β stimulates tumor progression by suppressing immune cells
and promoting factors that contribute to tumor metastasis. High levels of TGF-β
dampen the function and frequency of antigen presenting cells, cytotoxic T cells,
and helper T cells. Also, TGF-β (in combination with IL-2) has been implicated
in inducing an increased number of CD4+CD25+Fox3p+ regulatory T cells seen
in tumors [44]. These regulatory T cells (Tregs) modulate the function of effector
cells rendering them unable to continue their cytotoxic activity, leading to a weak
or non-existent immune response to cancerous cells [14, 94].
The immunosuppressive effects of TGF-β on immune cells strongly support
the development of TGF-β inhibitors to treat cancer. Several inhibitors of TGF-β
are in various stages of development (see [44] and the references therein). Several
clinical trials have evaluated TGF-β inhibition in cancer patients with some promis-
ing results. Unfortunately, while a few studies have shown the beneficial effects of
anti-TGF-β in tumor treatment (see [9, 10]), Terabe et al. demonstrate that deple-
tion of TGF-β is not always sufficient to elicit an effective immune response against
cancerous cells [44, 106]. Using a mouse model, Terabe et al. showed that treat-
ment with anti-TGF-β alone does not enhance the immune response. However, an
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anti-TGF-β treatment did appear to facilitate an enhanced immune response when
combined with an immune-boosting vaccine.
The goal of our present study is to understand part of the complex interplay
between cancer, the immune system, and the immunoregulatory mechanisms that
lead to ineffective immune responses. More specifically, we are interested in quanti-
fying the effects that anti-TGF-β and vaccine treatments might have on the stability
of the tumor-immune dynamic and how the combined treatment might contribute
to tumor clearance as opposed to tumor escape. In order to understand how the
suppression of regulatory mechanisms might affect a cancer vaccine, we develop a
mathematical model to analyze the effects of anti-TGF-β treatment when used in
conjunction with a vaccine as treatments for tumor growth. This is viewed as a step
in developing a framework within which experimentalists may test treatment proto-
cols prior to conducting their experiments. Our work is based on the experiments
of [106].
A number of mathematical models have been developed to describe tumor-
immune dynamics. A review of non-spatial tumor-immune models can be found in
[38]. ODE models provide a framework within which one can explore the interactions
among tumor cells and the alternate agents (such as immune cells, healthy tissue
cells, cytokines, etc.). A general, non-spatial tumor-immune model considers an
effector cell population (CTLs, NK Cells, etc.) interacting with tumor cells. In
the earliest models, these interactions are described by two equations, where the
immune cells play the role of the predator, while the tumor cells are the prey [69].
A framework for all such models is developed and analyzed in [36]. Many models
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incorporate different immuno-therapeutic strategies such as injection of cytokines
[22, 63], transfer of effector cells [63], or immunization with dendritic cells [23].
There are several mathematical models that specifically incorporate the effects
of TGF-β on tumor development [20, 26, 67, 76, 89, 112]. One such model that
considers the effects of TGF-β on tumor growth while also including a treatment
that consists of constant infusion of exogenous CTLs is developed in [66]. The model
developed in [62] specifically considers disrupting TGF-β production as a method
of tumor treatment. Their mathematical model describes tumor growth, immune
escape, and anti-TGF-β treatment. In contrast, this work mathematically studies
a combined therapy through TGF-β inhibition and CTL vaccine.
The structure of this chapter is as follows: In Section 4.2.1, we describe the
experimental background that was used as a basis for this work. In Section 4.2.2, we
present an ODE model of tumor growth that is then used to investigate the effects
of vaccinations and TGF-β inhibition. Model simulations and a stability analysis
are included in Section 4.3. The main results for the four treatment regimes are
shown in Figure 4.2. Closing remarks and directions for future work are given in
Section 4.4. The results of this chapter were accepted for publication in the Bulletin
of Mathematical Biology.
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4.2 A Model of Tumor Vaccine Enhancement by TGF-β Inhibition
4.2.1 Biological Background
Our mathematical model is based on the experimental data presented in [106].
In this study, Terabe et al. examined whether TGF-β neutralization can potentiate
immune responses caused by a CTL-inducing vaccine. Their goal was to determine
the conditions under which this enhanced immune response inhibits and/or elim-
inates tumor growth in a TC1 mouse tumor model. This particular tumor line
expresses the human papilloma virus (HPV) E6 and E7 genes (i.e. the tumor is
slightly immunogenic) and manifests in lung epithelial cells. Twenty thousand can-
cer cells were injected into the right flank of the mouse and four days after tumor
challenge, mice were immunized with HPV peptide. The TGF-β inhibitor used for
experiments was 1D11; a murine anti-TGF-β monoclonal antibody that neutralizes
all three isoforms of TGF-β. This antibody was shown to have minimal side effects
in normal, tumor-free animals. The main results of [106] can be summarized as
follows:
1. Blocking TGF-β enhances the effects of an anti-tumor peptide vaccine. In the
case where both treatments were given, the tumor burden was significantly
lower than any other treatment option tested; and 40% of mice remained
tumor free for at least 55 days after tumor challenge.
2. Anti-TGF-β enhances the quantity and the quality of the vaccine-induced
CD8+ CTL responses.
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3. The enhancement of the immune response was shown to not be due to:
• suppression of CD4+CD25+ Tregs.
• suppression of IL-17 producing T cells.
• Natural Killer T cell-induced TGF-β production by Myeloid-derived Sup-
pressor Cells.
The conclusion of the experimental study in [106] was that monotherapy with
anti-TGF-β did not have a significant impact on tumor growth. The anti-TGF-β
did, however, significantly enhance the efficacy of the peptide vaccine by inducing an
increased number of tumor antigen-specific CTLs, which is critical for the effective
elimination of tumors.
4.2.2 Mathematical Model
In order to quantitatively study the experimental setup of [106], we developed
a mathematical model. In this model, we follow the dynamics of the tumor size,
denoted T (t); TGF-β concentration, denoted B(t); activated cytotoxic effector cells,
denoted E(t); regulatory T cells, denoted R(t); and vaccine-induced cytotoxic ef-
fector cells, denoted V (t). A diagram of the different interactions between these








Figure 4.1: A diagram of the interactions between the different populations in the
mathematical model of tumor vaccine and TGF-β inhibition.
Our mathematical model is written as the following system of ODEs:
dT
dt















− rE − δ0RE − δ1E, (4.3)
dR
dt
= rE − δ1R, (4.4)
dV
dt
= g(t)− δ1V. (4.5)
Equation (4.1) describes the tumor size measured in mm2. The tumor follows
logistic growth dynamics with growth rate, a0, and carrying capacity, 1/c0. The
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second term on the RHS of (4.1) describes the ability of immune cells to induce
apoptosis of tumor cells. This clearance rate is inversely related to the amount
of TGF-β present in the system (i.e. TGF-β diminishes CTL ability to induce
apoptosis in tumor cells). The last term defines the action of vaccine cells on tumor
cells. Since vaccine cells are considered to be fully differentiated, they are assumed
to be unaffected by the inhibitory effects of TGF-β. Vaccine cells induce the death
of tumor cells at a rate δ0.
The dynamics of the concentration of TGF-β cytokine, measured in ng/ml,
are described in equation (4.2). Experimental evidence has shown that TGF-β
production by tumor cells is low for small tumors but “switches” on as the tumor
grows; promoting immune evasion [83]. The use of equation (4.2) as a model for
TGF-β production is described in [62]. As in [62], the maximum rate of TGF-β
production is represented by the parameter a1; c2 is the critical tumor size at which
the switch occurs; and the decay rate of the protein is d.
Equation (4.3) describes the dynamics of the number of effector T cells in the
system. The first term represents immune recruitment. Effector cells are activated
proportionally to the number of interactions with tumor cells. This term is multi-
plied by (1 + c3TB)
−1 to account for the combined negative effect of tumor growth
and TGF-β production on immune recruitment and proliferation. The parameter c3
represents the magnitude of the inhibition associated with tumor growth and TGF-
β. A proportion, r, of effector cells differentiate into regulatory T cells (a process
that is further discussed in the next paragraph). The final term of this equation
models the removal of effector T cells from the system. These cells have both a
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natural death rate; assumed to be the natural death rate for all effector cells, δ1;
and a death/removal rate that is proportional to the mass action interaction with
regulatory T cells, δ0. These magnitudes are assumed to be the same.
Equation (4.4) describes the number of Tregs in the regulatory T cell com-
partment. Though regulatory T cells originate from both CD4+ and CD8+ T cells
[96], this model follows the principles of minimal design by considering only CD8+
effector T cells as precursors to Tregs. The feedback mechanism in this model ap-
plies as long as CTLs induce the production and/or recruitment of Tregs. A similar
approach to simplifying the modeling adaptive regulation was taken in [58, 114].
In the model, Tregs differentiate from (or are recruited by) effector T cells at a
rate r. The second term is the rate at which Tregs die. These cells provide negative
feedback to the effector T cell population. Regulatory T cells should be considered
as removing effector T cells from the system rather than killing them. While it is
possible that effector T cells die upon interaction with regulatory T cells, that is not
necessarily the only explanation. As suggested in [60], it is also possible that some
effector cells might turn into memory cells, some might lose their effector function,
and others might migrate away from the lymph node and carry out effector functions
in the periphery. For the purposes of the model, suppressed cells, cells that have
migrated, and dead cells are irrelevant to the dynamics, so we consider them all to
be removed from the system.
Equation (4.5) describes the vaccine. The vaccine is modeled as an influx of
activated tumor-specific cytotoxic T cells. These cells are impulsively introduced
into the system at day 3 and are considered to be fully differentiated (i.e. no longer
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dividing). If the vaccine is given,
g(t) = g0δ(t− 3),
where g0 = 5, 000 and δ(t) is the Dirac delta function. If the vaccine is withheld,
g(t) ≡ 0.
Vaccine cells have a natural death rate of δ1. This aspect of the model deviates from
the experimental setup. In the experiment, a peptide vaccine is given to induce the
production and proliferation of CTLs, while here, we model the vaccine as a direct
injection of CTLs. The model vaccine is more in line with vaccination through
adoptive T cell transfer, and therefore, might make the model more adaptable to
experiments involving less antigenic tumors. Some of the consequences of this design
decision will be discussed in the Sections 4.3 and 4.4.
4.3 Results




















































































































































































































































































































































































































































































































The list of the parameters used in our simulations is given in Table 4.1. The
parameters a0 and c0 were approximated using a nonlinear least squares fit to the
control data presented in [106]. Baseline values for a1, c2 and d were obtained from
[62]. The value for the immuno-suppressive effects of TGF-β, c1, was estimated
based on data presented in [106]. The rate of effector cells that differentiate into
regulatory cells, r, was given in [58] and falls in accordance with the range presented
in [96]. A parameter sensitivity analysis was performed on the model parameters.
The results of this analysis are presented later.
4.3.1 Simulations
Numerical solutions of (4.1)–(4.5) were obtained using Matlab’s ODE23 solver.
Starting with the initial measurements presented in [106], we begin our simulations
at Day 3 after tumor presentation and conclude all simulations on day 30. At the
initial time point, we assume that tumor antigenicity has led approximately 100
activated effector T cells to be present at the site of the tumor. This is consistent
with the number of mouse precursor CTLs presented in [16] in which they estimated
the number of Db GP33-specific CD8 T cells to be 2× 102.
Figure 4.2 shows results of our simulations in the four treatment regimes along
with the corresponding experimental data. The simulation and the control data to
which it was fit are shown in Figure 4.2(a). As previously mentioned, the control
data set was used to approximate some of the model parameters. We calibrated the
no-treatment model to follow the growth trend of the experimental data. While the
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(c) TGF-β Inhibitor Treatment






















(d) Combined Vaccine and TGF-β Inhibition
Figure 4.2: The dynamics of the tumor size in four treatment regimes. Shown are
the results of the numerical simulations along with the experimental data from [106]
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precise timing of the observed phenomena is not captured by the present model,
it is the qualitative aspects of the increase and decrease in the tumor size that we
are seeking. The goal of this model is to capture the phenomena of tumor escape
with monotherapy, and the peak tumor size and tumor eradication in the case of
a combined therapy. These biological aspects are clearly captured by the current
model.
In Figure 4.2(b), the vaccine treatment is modeled as an addition of 5, 000
effector T cells to the vaccine equation at day 3 of simulation. These cells are
assumed to be resistant to TGF-β. In this case, there is a steady growth of the
tumor throughout the simulation. The vaccine facilitates conditions that lead to
a smaller tumor at the final time step. These cells do not multiply once added to
the system, and hence the benefit of the vaccine slowly diminishes at the natural
death rate for vaccine cells. This means that if the initial size of the vaccine is not
large enough to overpower the tumor growth, then the tumor will always escape
immunosurveillance.
We model TGF-β inhibition as an increase of c2 from 300 to 7, 000. This
effectively delays the “switch” of TGF-β production by approximately 8 days. The
results of this simulation are shown in Figure 4.2(c). In this case, we see that the
tumor remains small for the duration of TGF-β inhibition. However, soon after the
TGF-β levels begin to recover, tumor growth quickly becomes uncontrolled. Similar
results were seen for other values of c2. In simulation, we see that singular TGF-β
inhibition leads to a reduction in final tumor load at 30 days of simulation. This
initial delay of tumor growth differs from the original data in [106], however the
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final result of uncontrolled tumor growth remains similar.
The final case, Figure 4.2(d), shows the predictions of the model when both
TGF-β and vaccine treatments are administered. Similar to the experimental results
in [106], we see that a combined treatment is sufficient to induce tumor eradication.
Model simulations lead to agreement with experiments concerning the peak tumor
size. The timing of this maximum tumor size will be the addressed in the discussion.
Simulations show an initial phase of tumor growth, but at approximately day 21,
the immune system is able to clear the tumor. This suggests that such an outcome
is the result of long-term presence of CTLs provided by the vaccine, in combination
with the TGF-β inhibitor that provides an initial boost to the host’s native immune
system.
Figure 4.3 compares the tumor growth in all four treatment regimes. It is clear
that while monotherapy results in a slowing down of the tumor growth, the tumor
is still able to escape immunosurveillance and grow uncontrolled. Only in the case
of dual therapy is the immune system able to eradicate the tumor.
We show the dynamics of the individual populations in the control case and
the combined treatment case in Figure 4.4 and Figure 4.5. Figures 4.4(a) and
4.5(a) show how the tumor population changes over time. Figures 4.4(b) and 4.5(b)
demonstrate the dynamics of the TGF-β concentration. In the no-treatment scenario
4.4(b), we see that the TGF-β levels are increasing with the tumor size. These high
levels of TGF-β, particularly at later time points, contributes to the suppression of
the effector T cell concentration as seen in Figure 4.4(c). In the combined treatment
scenario, TGF-β levels are kept very low (see Figure 4.5(b)). This contributes to a
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Figure 4.3: A comparison of the dynamics of the tumor size for all treatment regimes.
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(a) No Treatment: Tumor Size





















(b) No Treatment: TGF-β Concentration














(c) No Treatment: CTL Population












(d) No Treatment: Treg Population
Figure 4.4: Simulated population dynamics of the individual populations in the
control case: (a) Tumor size (mm2), (b) TGF-β concentration (ng/ml), (c) CTL
population (number of), (d) Treg population (number of).
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(a) Combined Treatment: Tumor Size



















(b) Combined Treatment: TGF-β Concentration


















(c) Combined Treatment: CTL Population















(d) Combined Treatment: Treg Population
Figure 4.5: Simulated population dynamics of the individual populations with com-
bined treatment: (a) Tumor size (mm2), (b) TGF-β concentration (ng/ml), (c) CTL
population (number of), (d) Treg population (number of).
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robust immune response peaking on Day 16 with just under 140, 000 CTLs present
in the system (Figure 4.5(c)). The regulatory T cell populations are shown in
Figures 4.4(d) and 4.5(d). Though these regulatory cells are effective at ending the
immune response in both cases, the maximum ratio of regulatory cells to T cells
is 0.075 in the no-treatment case and 0.062 in the case of a combined treatment.
This aligns with the results of [106] which indicated that TGF-β inhibition does not
suppress Treg production, but it does increase the ratio of effectors to Tregs in each
of the treatment scenarios.
4.3.2 Equilibrium Analysis
We solve for the steady states of the control system by the usual manner of
setting the left hand sides of (4.1) – (4.4) equal to 0 and solving for T , B, R, and
E. The calculation for this is shown below.
We begin with the following system:











− rE − δ0RE − δ1E, (4.8)
0 = rE − δ1R. (4.9)
Case 1 T = 0 or B = 0:
A simple consideration of (4.7) shows T = 0⇔ B = 0.
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From (4.9), we get









R(r + δ0R + δ1).
Hence, in Case 1, steady states will arise from two possible sub-cases: R = 0
or r + δ0R + δ1 = 0.
Case 1.1 R = 0.
From (4.10) it follows that R = 0⇔ E = 0. Hence, we have the all zero solution of
T = B = E = R = 0.
Case 1.2 r + δ0R + δ1 = 0:
0 = r + δ0R + δ1,
⇒ R = −(r + δ1)
δ0
.
Since δ0, δ1, r > 0, we have R =
−(r+δ1)
δ0
< 0. But we are only interested in
non-negative solutions. Hence this is not a biologically feasible solution.
Case 2 T 6= 0 and B 6= 0.
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d(c2 + T 2)
. (4.11)
Case 2.1 E = 0 and R = 0.
Under these assumptions, (4.6) reduces to
0 = a0T (1− c0T ).
Hence, T = 1
c0


















E = R = 0.
Case 2.2 E 6= 0 and R 6= 0.
We will first obtain two equations describing E in terms of T. We then proceed by
numerically obtaining solutions to this 2 equation system.
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We begin by substituting (4.11) into (4.6) and solving for E.










= a0(1− c0T ),
δ0dE(c2 + T
2)
dc2 + T 2(a1c1 + d)
= a0(1− c0T ),
E =
a0(1− c0T )[dc2 + T 2(a1c1 + d)]
δ0d(c2 + T 2)
. (4.12)
We continue by substituting (4.11) into (4.8) and solving for E.
0 =
fT







































We are looking for E and T such that both (4.12) and (4.13) are satisfied. In
Figure 4.6, we graph the function g(T) for the parameter values given by Table 4.1.
This function is obtained by subtracting the RHS of (4.12) and (4.13) from each
other and is defined as :
g(T ) =
a0(1− c0T )[dc2 + T 2(a1c1 + d)]
δ0d(c2 + T 2)
− δ1fTd(c2 + T
2)



















Student Version of MATLAB
I II
Figure 4.6: A graph of g(T ) (from (4.14)) for the relevant values of T . Visual
inspection shows g(T ) has two regions containing possible zeros. These regions of
interest are circled and labeled (I) and (II).
There are two areas of interest that possibly contain zeros. They are labeled
(I) and (II) in Figure 4.6. Area (I) of Figure 4.6 is shown in Figure 4.7(a), and
for the given parameters, (4.14) has no zeros in this region. Area (II) of Figure 4.6
is shown in Figure 4.7(b). Using bisection method, we numerically locate a zero at
T0 = 368.87. Substituting T0 into (4.12) or (4.13), yields E = −1.00052. Again,
we are only interested in steady states with non-negative values for all components.
Hence, this is not a biologically feasible solution and does not need to be further
considered.
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Student Version of MATLAB
(a) A graph of g(T ) in region I of Figure 4.6.











Student Version of MATLAB
(b) A graph of g(T ) in region II of Figure 4.6.
Figure 4.7: g(T ) graph d in the regions of interest circled in Figure 4.6.
In order to analyze the stability of these equilibrium points, we consider the
Jacobi matrix of (4.1) – (4.4) with V ≡ 0. It is as follows:
















− r − δ0R− δ1 −δ0E
0 0 r −δ1

(4.15)
The steady state analysis of the system revealed two feasible (non-negative)
steady states. Considering the eigenvalues of (4.15) when evaluated at these equi-




E = R = 0, is stable while the all zero, T = B = E = R = 0, solution is un-
stable. This implies that even in the case of successful treatment, simulations will
eventually lead to a non-zero tumor equilibrium. Hence, we consider treatment to
be successful if the size of the tumor is reduced to less than the size of one cell
or if the tumor is reduced to a “manageable” size for the duration of simulation.
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As previously mentioned, all other steady states contain at least one negative com-
ponent, implying that they are not feasible for the given biological system. This
implies that there is no “small-tumor” equilibrium in which a tumor is maintained
at a non-zero, non-lethal size by immune cells. In Figure 4.8, we present a phase
portrait displaying the relation between tumor size and effector cells when combined
treatment is simulated. Here we see that for tumors with high antigenicity, the tu-
mor load is reduced to near zero for a period of time before the immune response
is no longer able to control the tumor. For mildly antigenetic tumors, effector cells
are only mildly stimulated by the presence of the tumor and cannot impose tumor
shrinkage to manageable levels.





























Student Version of MATLAB
Figure 4.8: Effector T cell versus tumor size phase portrait when combined treat-
ment is simulated with different levels of tumor antigenicity. Depending on the
antigenicity, the tumor load is reduced to near zero for a period of time before the
immune response is no longer able to control the tumor.
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To determine the parameters to which the model is most sensitive, we per-
formed a sensitivity analysis. This was done in a one-at-a-time fashion by varying
each parameter over a range of values centered around a baseline value and observ-
ing the size of the tumor at the end of 30 simulated days. Figure 4.9 shows the
results of this parameter sensitivity analysis with Figure 4.9(a) and Figure 4.9(b)
displaying the results for the no treatment case and the combined treatment case,
respectively. In the no treatment case, variations of parameters leads to very little
changes in the final tumor size. This shows that, for a wide range of cases, a lack
of treatment will lead to uncontrolled tumor growth. In the case of combined treat-
ment, the system was found to be sensitive to a1, the parameter quantifying the
maximal production rate of TGF-β, c2, the quantity describing the size at which a
tumor begins to produce TGF-β, and f , the quantification of a tumor’s antigenic-
ity. The system is most sensitive to the parameter f which aligns with the results
concerning the corresponding parameters in [29] and [62].
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(a) No Treatment Sensitivity Analysis. Baseline values: c1 = 100, a1 = 0.3, c2 = 300,
d = 7× 10−4, f = 0.62, c3 = 300, r = 0.01









































(b) Combined Treatment Sensitivity Analysis. Baseline values: c1 = 100, a1 = 0.3, c2 = 7×103,
d = 7× 10−4, f = 0.62, c3 = 300, r = 0.01
Figure 4.9: Model sensitivity analysis. Done by varying each parameter over a range
of values centered around a baseline value and observing the size of the tumor at the
end of 30 simulated days. (a) No treatment case: variations of parameters leads to
very little changes in the final tumor size. (b) Combined treatment: the system was
found to be sensitive to a1, the parameter quantifying the maximal production rate
of TGF-β, c2, the quantity describing the size at which a tumor begins to produce
TGF-β, and f , the quantification of a tumor’s antigenicity.
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Due to the expression of the HPV E6 and E7 genes, the type of tumor consid-
ered for the model is considered to be reasonably antigenic. What happens if a less
antigenic tumor is considered? This case is considered in Figure 4.10. Here, we re-
duce the value of the tumor antigenicity parameter, f . As previously mentioned, our
sensitivity analysis suggests that the final tumor size is sensitive to this parameter.
Figure 4.10 shows the results of reducing f from 0.62 by 10% to 0.56. In this case,
there is a mild immune reaction, peaking around day 20 after tumor presentation.
This immune response is capable of reducing the size of the tumor. However, the
reduction of antigenicity causes the immune response to be unsustainable, leading
to the eventual unbounded growth of the tumor.


















Figure 4.10: A simulated tumor growth for a mildly antigenic tumor (f = 0.56)
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4.4 Discussion
The qualitative aspects of the simulations align with the data described in
[106]. Obtaining precise quantitative matches with the data proved difficult as the
data was presented as averages without error estimates or statistical measurements.
However, the general characteristics of each of the four cases has been captured
by the present model. For instance, in the case where both vaccine and TGF-β
inhibitors were given, the model predicts that the tumor size will reach its peak
on day 5 and tumor eradication will occur on day 21. The data suggests that
these events occur respectively on days 15 and 27. Also, unlike the data presented
by Terabe et al., in which TGF-β inhibition lead to no significant delay in tumor
growth, the model displays a slowed down (yet uncontrollable) tumor growth in the
case of a TGF-β treatment. Modifying the model to better capture the timing of
these events will be considered in future work. The choice of modeling the vaccine
as an adoptive T cell transfer as opposed to a peptide vaccine could be one of the
causes for the discrepancy in timing. In the model, T cells are immediately available
to begin killing tumor cells, where as in the case of a peptide vaccine there would
be a delay between the time of the vaccine and the time that newly recruited CTLs
would be activated and available. This design choice contributes to the lack of
need of delay differential equations and makes the model amendable to the study of
questions regarding adoptive T cell transfer.
The means by which tumors evolve is nontrivial and all aspects of tumor treat-
ment cannot be included in a single model. Our mathematical model highlights
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just one possible way of combining tumor treatments to promote tumor eradication
through an immune response. A number of biological experiments and mathematical
models have highlighted the fact that immunotherapy alone is not always effective
in eradicating a tumor [1, 22, 27, 33, 44, 62, 106]. Here we show how combined
immunotherapy treatments might work through different mechanisms to promote
tumor clearance. Simulations of model (4.1)–(4.5) show qualitative agreement with
the data in [106]. In the case of administering either the vaccine or the TGF-β
inhibitor, we see a temporary delay in tumor growth; but, this delay is not sus-
tainable over time. The vaccine alone is not enough to eradicate the tumor, and
though TGF-β is inhibited in the initial days of tumor presentation, the protein level
recovers soon thereafter, regaining its immunosuppressive effects. Tumor eradica-
tion requires a combination of therapeutic approaches. Our results suggest that the
vaccine allows for the development of a significant and long-term immune response
that is minimally affected by the TGF-β that is present at later time points. The
TGF-β inhibitor provides conditions that help the populations of immune cells to
expand during the initial phases of tumor presentation. One very pertinent follow
up question is: does one treatment amplify the other or do they act independently of
each other? The data collected in [106] seems to support the notion that one treat-
ment amplifies the other, but further study is required in order to reach a conclusive
understanding.
The results of this work provide an initial analytical framework for studying
immunotherapy via TGF-β inhibition in combination with vaccine treatment. Opti-
mally, future studies should be conducted in combination with experiments. Control
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of nonlinear processes will play a vital role in determining the effectiveness of these




Immune regulation is an essential component of the cell mediated immune
response. Failure of regulatory control of the immune system can lead to a number
of complications including autoimmune diseases and immune deficiency. Despite
significant study of these topics, many immunoregulatory mechanisms are not well
understood. In an effort to increase understanding of this topic, we use mathematical
models to study the dynamics of immune regulation with a focus on the role of
immune regulation in the primary immune response, immunodominance and tumor
growth.
In chapters 2 and 3 we developed mathematical models of the primary immune
response. We followed the hypothesis that regulatory T cells are an essential compo-
nent in suppressing a normal immune response and included adaptive regulation as
a key component of each of our models. We also highlighted the biological evidence
regarding the ability of regulatory T cells to lose their regulatory capabilities and
become immune promoting cells. In Chapter 2, we included the adaptive regulation
and regulatory T cell switching mechanisms in an ODE model. We demonstrated
that the model displays the expected expansion/contraction dynamics and con-
ducted a study of the effects of Treg switching. Active suppression by regulatory
T cells was shown to be a plausible mechanism of immune contraction. Negative
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feedback provided by regulatory T cells was able to control the immune expansion
and return the system to homeostasis. The regulatory T cell switching mechanism
was shown to increase the robustness of the system, allowing for recovery from an
unbalanced or even helper T cell deficient system.
A further exploration of these mechanisms was done in the context of a more
detailed DDE model of the immune response in Chapter 3. Here, we demonstrated
that when compared to previous mathematical models, our model shows increased
robustness with respect to precursor T cell frequencies. Consistent with results
found in Chapter 2, we identified a plausible range for the rate of Treg switching.
This model is also used to study the effects of regulatory T cell switching on immun-
odominance. Treg switching was shown to affect immunodominance hierarchies in
two ways. First, increasing the switching rate was shown to increase the magnitude
of the immune response within a T cell clone hierarchy. Also, larger values of this
rate were shown to increase the ability of weaker T cell clones to compensate for
more dominant clones that were removed.
There are many avenues for further study within the topic of immune regula-
tion. A spatial component can be added to the system by separating the lymph node
from the infected tissue. Different cells have different functionalities depending on
their environment and adding a spatial component would allow to account for these
different functionalities. In such a compartmental model, one of the main questions
to investigate would be whether regulatory cells are required at the infection site or
if their presence in the lymph nodes is sufficient to robustly regulate the system.
All of the models presented here model the response to acute infections. These
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models can be extended to study other occurrences such as chronic diseases or auto-
immunity. It is unclear how memory cells influence the regulation of the immune
system. Adding a memory T cell component is a key step in extending the appli-
cability of our models from short-term, viral infections to chronic illnesses. Finally,
regulatory T cells may play a key role in Human Immunodeficiency Virus (HIV)
infections. HIV mainly affects activated helper T cells, leading to insufficient levels
of these immune cells. Regulatory cells play a dual role in these infections. They
reduce the number of activated helper T cells in the body, decreasing the number of
possible targets for the virus. Yet this reduction also suppresses other mechanisms
by which the immune system might fight the virus. Modeling the role that these
cells play in HIV infections could lead to a better understanding of the nature of
this disease.
In Chapter 4, we highlighted how immunotherapy might be used to overcome
the effects of two immuno-regulatory agents exploited by cancer: regulatory T cells
and the Transforming Growth Factor (TGF)-β protein. Our aim with this model
was to understand part of the complexity of tumor immunology. Using the data
presented in [106], we developed a mathematical model to gain insight into the co-
operative interaction between anti-TGF-beta and vaccine treatments. Consistent
with experiments of [106], our model demonstrated that monotherapy is not suffi-
cient to eradicate a tumor and that tumor eradication requires the combination of
these therapeutic approaches. Our results suggest that the vaccine provides a long-
term immune response that is unaffected by the TGF-β present at later time points.
The TGF-β inhibitor provides conditions that help the populations of immune cells
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to expand during the initial phases of tumor presentation.
The alignment of our model with biological data suggests that this model
can potentially be used in guiding future experiments that are aimed at studying
immunotherapy as a treatment for cancer. The model can be potentially used to
determine an optimal protocol for the administration of these immunotherapeutic
approaches. To that end, optimal/suboptimal control of nonlinear processes will
play a vital role in determining treatment protocols. A mathematical model of
optimal control of multiple modes of tumor treatment is presented in [70]. Similar
techniques can be used to consider combined anti-TGF-β and vaccine treatments.
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ment in näıve t cells. Journal of Experimental Medicine, 199(10):1401–1408,
2004.
[6] A. Ay and D. N. Arnosti. Mathematical modeling of gene expression: a guide
for the perplexed biologist. Critical Reviews in Biochemistry and Molecular
Biology, 46(2):137–51, Apr. 2011.
[7] V. P. Badovinac, J. S. Haring, and J. T. Harty. Initial T cell receptor transgenic
cell precursor frequency dictates critical aspects of the CD8(+) T cell response
to infection. Immunity, 26(6):827–41, June 2007.
[8] C. Baecher-Allan, V. Viglietta, and D. A. Hafler. Human CD4+CD25+ reg-
ulatory T cells. Seminars in Immunology, 16(2):89 – 98, 2004.
[9] Baylor College of Medicine. Safety study of injections of autolo-
gous/allogeneic TGFBeta-resistant LMP2A-specific cytotoxic T lymphocytes
(CTL). Bethesda: National Library of Medicine, 2006. Available from
http://clinicaltrials.gov/ct/show/NCT00368082.
[10] Baylor College of Medicine. Her2 and TGFBeta in treatment of Her2 positive
lung malignancy (HERCREEM). Bethesda: National Library of Medicine,
2009. Available from http://clinicaltrials.gov/ct/show/NCT00368082.
[11] Y. Belkaid, C. Piccirillo, S. Mendez, E. Shevach, and D. Sacks. CD4+CD25+
regulatory T cells control leishmania major persistence and immunity. Nature,
420(6915):502–507, 2002.
[12] N. Bellomo, E. De Angelis, and L. Preziosi. Multiscale modeling and mathe-
matical problems related to tumor evolution and medical therapy. Journal of
Theoretical Medicine, 5(2):111–136, 2003.
101
[13] E. Bettelli, T. Korn, M. Oukka, and V. K. Kuchroo. Induction and effector
functions of T(H)17 cells. Nature, 453(7198):1051–7, June 2008.
[14] M. Beyer and J. L. Schultze. Regulatory T cells in cancer. Blood, 108(3):804–
11, Aug. 2006.
[15] H. W. Blanch and D. S. Clark. Biochemical engineering. Marcel Dekker Inc.,
New York, 1997.
[16] J. N. Blattman, R. Antia, D. J. D. Sourdive, X. Wang, S. M. Kaech, K. Murali-
Krishna, J. D. Altman, and R. Ahmed. Estimating the precursor frequency
of naive antigen-specific CD8 T cells. Journal of Experimental Medicine,
195(5):657–64, Mar. 2002.
[17] J. N. Blattman and P. D. Greenberg. Cancer immunotherapy: a treatment
for the masses. Science, 305(5681):200–5, July 2004.
[18] L. Brandt, T. Benfield, H. Mens, L. N. Clausen, T. L. Katzenstein, A. Foms-
gaard, and I. Karlsson. Low level of regulatory T cells and maintenance of
balance between regulatory T cells and TH17 cells in HIV-1-infected elite con-
trollers. Journal of Acquired Immune Deficiency Syndromes, 57(2):101–108,
2011.
[19] F. M. Burnet. Immunological surveillance in neoplasia. Immunological Re-
views, 7(1):3–25, 1971.
[20] H. Byrne and S. Gourley. The role of growth factors in avascular tumour
growth. Mathematical and Computer Modelling, 26(4):35–55, Aug. 1997.
[21] R. Callard, A. J. George, and J. Stark. Cytokines, chaos, and complexity.
Immunity, 11(5):507–513, Nov. 1999.
[22] A. Cappuccio, M. Elishmereni, and Z. Agur. Cancer immunotherapy by
interleukin-21: potential treatment strategies evaluated in a mathematical
model. Cancer Research, 66(14):7293–300, July 2006.
[23] F. Castiglione and B. Piccoli. Optimal control in a model of dendritic
cell transfection cancer immunotherapy. Bulletin of Mathematical Biology,
68(2):255–74, Feb. 2006.
[24] A. Cerwenka and S. L. Swain. TGF-β1: immunosuppressant and viability
factor for T lymphocytes. Microbes and Infection, 1(15):1291–6, Dec. 1999.
[25] W. Chen, W. Jin, N. Hardegen, K. Lei, L. Li, N. Marinos, G. McGrady, and
S. Wahl. Conversion of peripheral CD4+CD25- näıve T cells to CD4+CD25+
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automata-based mathematical model for thymocyte development. PloS One,
4(12):e8233, Jan. 2009.
[103] M. B. Sporn. TGF-β: 20 years and counting. Microbes and Infection,
1(15):1251–1253, Dec. 1999.
108
[104] L. S. Taams, M. Vukmanovic-Stejic, J. Smith, P. J. Dunne, J. M. Fletcher,
F. J. Plunkett, S. B. Ebeling, G. Lombardi, M. H. Rustin, J. W. J. Bijlsma,
F. P. J. G. Lafeber, M. Salmon, and A. N. Akbar. Antigen-specific T cell
suppression by human CD4+CD25+ regulatory T cells. European Journal of
Immunology, 32(6):1621–30, June 2002.
[105] Q. Tang, J. Y. Adams, A. J. Tooley, M. Bi, B. T. Fife, P. Serra, P. Santamaria,
R. M. Locksley, M. F. Krummel, and J. A. Bluestone. Visualizing regulatory
T cell control of autoimmune responses in nonobese diabetic mice. Nature
Immunology, 7(1):83–92, Jan. 2006.
[106] M. Terabe, E. Ambrosino, S. Takaku, J. J. O’Konek, D. Venzon, S. Lonning,
J. P. McPherson, and J. A. Berzofsky. Synergistic enhancement of CD8+ T
cell-mediated tumor vaccine efficacy by an antitransforming growth factor-β
monoclonal antibody. Clinical Cancer Research, 15(21):6560–9, 2009.
[107] M. Tsuji, N. Komatsu, S. Kawamoto, K. Suzuki, O. Kanagawa, T. Honjo,
S. Hori, and S. Fagarasan. Preferential generation of follicular B helper T
cells from Foxp3+ T cells in gut Peyer’s patches. Science, 323(5920):1488–92,
Mar. 2009.
[108] M. J. van Stipdonk, G. Hardenberg, M. S. Bijker, E. E. Lemmens, N. M.
Droin, D. R. Green, and S. P. Schoenberger. Dynamic programming of CD8+
T lymphocyte responses. Nature Immunology, 4(4):361–5, Apr. 2003.
[109] M. J. van Stipdonk, E. E. Lemmens, and S. P. Schoenberger. Näıve CTLs
require a single brief period of antigenic stimulation for clonal expansion and
differentiation. Nature Immunology, 2(5):423–9, May 2001.
[110] H. von Boehmer. Mechanisms of suppression by suppressor T cells. Nature
Immunology, 6(4):338–344, 2005.
[111] Y. Y. Wan and R. A. Flavell. Regulatory T-cell functions are subverted and
converted owing to attenuated Foxp3 expression. Nature, 445(7129):766–70,
Feb. 2007.
[112] S. E. Wang, P. Hinow, N. Bryce, A. M. Weaver, L. Estrada, C. L. Arteaga,
and G. F. Webb. A mathematical model quantifies proliferation and motility
effects of TGF-β on cancer cells. Computational and Mathematical Methods
in Medicine, 10(1):71–83, 2009.
[113] S. Wilson and D. Levy. A mathematical model of the enhancement of tu-
mor vaccine efficacy by immunotherapy. Bulletin of Mathematical Biology,
(accepted).
[114] S. N. Wilson, P. Lee, and D. Levy. A mathematical model of the primary t cell
response with contraction governed by adaptive regulatory T cells. In K. E.
Herold, W. E. Bentley, and J. Vossoughi, editors, Proc. IFMBE, volume 32,
pages 209–212. Springer, 2010.
109
[115] K. Wing, Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari,
T. Nomura, and S. Sakaguchi. CTLA-4 control over Foxp3+ regulatory T cell
function. Science, 322(5899):271–275, Oct. 2008.
[116] D. Wodarz and A. R. Thomsen. Effect of the CTL proliferation program on
virus dynamics. International Immunology, 17(9):1269–1276, September 2005.
[117] T. Yamaguchi, K. Hirota, K. Nagahama, K. Ohkawa, T. Takahashi, T. No-
mura, and S. Sakaguchi. Control of immune responses by antigen-specific
regulatory T cells expressing the folate receptor. Immunity, 27(1):145–159,
2007.
[118] S. Yamazaki, T. Iyoda, K. Tarbell, K. Olson, K. Velinzon, K. Inaba, and
R. Steinman. Direct expansion of functional CD25+ CD4+ regulatory T
cells by antigen-processing dendritic cells. Journal of Experimental Medicine,
198(2):235–247, 2003.
[119] A. Yates, C. Bergmann, J. L. Van Hemmen, J. Stark, and R. Callard.
Cytokine-modulated regulation of helper T cell populations. Journal of The-
oretical Biology, 206(4):539–60, Oct. 2000.
[120] X. Zhou, S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Mart́ınez-
Llordella, M. Ashby, M. Nakayama, W. Rosenthal, and J. A. Bluestone. In-
stability of the transcription factor Foxp3 leads to the generation of pathogenic
memory T cells in vivo. Nature Immunology, 10(9):1000–7, Sept. 2009.
110
